US20220218790A1 - Parathyroid hormone fusion polypeptide - Google Patents
Parathyroid hormone fusion polypeptide Download PDFInfo
- Publication number
- US20220218790A1 US20220218790A1 US17/708,394 US202217708394A US2022218790A1 US 20220218790 A1 US20220218790 A1 US 20220218790A1 US 202217708394 A US202217708394 A US 202217708394A US 2022218790 A1 US2022218790 A1 US 2022218790A1
- Authority
- US
- United States
- Prior art keywords
- fusion polypeptide
- seq
- amino acid
- pth
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 166
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 152
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 151
- 230000004927 fusion Effects 0.000 title claims abstract description 148
- 108090000445 Parathyroid hormone Proteins 0.000 title claims description 48
- 102000003982 Parathyroid hormone Human genes 0.000 title claims description 46
- 239000000199 parathyroid hormone Substances 0.000 title claims description 45
- 229960001319 parathyroid hormone Drugs 0.000 title claims description 45
- 208000000038 Hypoparathyroidism Diseases 0.000 claims abstract description 14
- 102000043299 Parathyroid hormone-related Human genes 0.000 claims abstract description 13
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 63
- 102100020948 Growth hormone receptor Human genes 0.000 claims description 44
- 108010051696 Growth Hormone Proteins 0.000 claims description 29
- 239000012634 fragment Substances 0.000 claims description 29
- 108020003175 receptors Proteins 0.000 claims description 29
- 102000018997 Growth Hormone Human genes 0.000 claims description 28
- 239000000122 growth hormone Substances 0.000 claims description 28
- 230000027455 binding Effects 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 20
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 230000028327 secretion Effects 0.000 claims description 17
- 235000001014 amino acid Nutrition 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 16
- 102000039446 nucleic acids Human genes 0.000 claims description 16
- 125000000539 amino acid group Chemical group 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 239000013598 vector Substances 0.000 claims description 12
- 241000282414 Homo sapiens Species 0.000 claims description 10
- 108010068542 Somatotropin Receptors Proteins 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 238000007792 addition Methods 0.000 claims description 7
- 230000004048 modification Effects 0.000 claims description 7
- 238000012986 modification Methods 0.000 claims description 7
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 claims description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 229930003316 Vitamin D Natural products 0.000 claims description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 230000003054 hormonal effect Effects 0.000 claims description 4
- 235000019166 vitamin D Nutrition 0.000 claims description 4
- 239000011710 vitamin D Substances 0.000 claims description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 4
- 229940046008 vitamin d Drugs 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 108010005905 delta-hGHR Proteins 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 3
- 125000000430 tryptophan group Chemical class [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 abstract description 9
- 238000011282 treatment Methods 0.000 abstract description 8
- 230000000849 parathyroid Effects 0.000 abstract description 6
- 108090000623 proteins and genes Proteins 0.000 description 39
- 102000004169 proteins and genes Human genes 0.000 description 37
- 235000018102 proteins Nutrition 0.000 description 35
- 108010033419 somatotropin-binding protein Proteins 0.000 description 35
- 210000004027 cell Anatomy 0.000 description 33
- 102000005962 receptors Human genes 0.000 description 28
- 108010076504 Protein Sorting Signals Proteins 0.000 description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
- 239000011575 calcium Substances 0.000 description 13
- 229910052791 calcium Inorganic materials 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 description 9
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 description 9
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 3
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010864 dual luciferase reporter gene assay Methods 0.000 description 3
- 102000058004 human PTH Human genes 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000002990 parathyroid gland Anatomy 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NNRMZXDHMCWWRV-RHBZDGMUSA-N (2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-carboxypropanoyl]amino]hexanoyl]amino]acetyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-carboxypropanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxybutanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]-3-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](C)N)C(C)C)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)C1=CN=CN1 NNRMZXDHMCWWRV-RHBZDGMUSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 101000589873 Homo sapiens Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000242739 Renilla Species 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010012543 amino-terminal parathyroid hormone Proteins 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 230000003491 cAMP production Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 108010045398 parathyroid hormone-related peptide (1-36) Proteins 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- ZKMHNHRVLHRELZ-YQEQSJBHSA-N (4S)-4-[[(2S)-5-amino-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-5-[[(2S)-4-carboxy-1-[[(2S)-1-[[(2S)-4-carboxy-1-[[(2S,3R)-1-[[(2S)-1-[[(1S)-1-carboxy-3-methylsulfanylpropyl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O ZKMHNHRVLHRELZ-YQEQSJBHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- 101100188555 Arabidopsis thaliana OCT6 gene Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 101710099093 Growth hormone receptor Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000009612 Laryngismus Diseases 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 description 1
- 101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- LZCZIHQBSCVGRD-UHFFFAOYSA-N benzenecarboximidamide;hydron;chloride Chemical compound [Cl-].NC(=[NH2+])C1=CC=CC=C1 LZCZIHQBSCVGRD-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 102000051132 human PTH1R Human genes 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940078710 natpara Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000013878 renal filtration Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 108010030159 thrombin receptor peptide 14 Proteins 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the disclosure relates to long acting parathyroid hormone fusion polypeptides comprising a receptor polypeptide wherein the receptor polypeptide is a parathyroid hormone receptor and/or growth hormone receptor; nucleic acid molecules encoding said fusion polypeptides; vectors adapted to express said fusion polypeptides; cells transformed or transfected with said nucleic acids or vectors; and use of said polypeptides in the treatment of hypoparathyroidism.
- hypoparathyroidism characterised by low parathyroid hormone (PTH) levels, is a rare condition and is either congenital or more often acquired following surgery to the neck.
- PTH parathyroid hormone
- PTH is secreted by the four parathyroid glands which are located next to the thyroid gland in the neck and controls calcium homeostasis, vitamin D-dependent calcium absorption, renal calcium reabsorption and renal phosphate clearance.
- PTH stimulates the release of calcium from the bone and enhances absorption of calcium in the intestine.
- Reduced PTH levels lead to hypocalcaemia and include symptoms such as neuromuscular irritability, including paraesthesia, muscle twitching, laryngeal spasms, tetany and seizures and can lead, if untreated to death.
- PTH is an 84-amino acid long polypeptide comprising a 34 long amino acid N-terminal biologically active domain which was found to be an effective PTH receptor agonist.
- PTH recombinant PTH is administered as a daily subcutaneous injection.
- PTH is known to be unstable in vitro and has a short half-life in vivo resulting in fluctuating PTH levels which are associated with nausea and vomiting.
- Compositions stabilising PTH in vitro are disclosed in U.S. Pat. Nos. 7,550,434, 7,144,861, 6,770,623, WO2006/129995 or WO2013/108235, and recombinant PTH analogues with enhanced pharmacokinetics and pharmacodynamics comprising a modified PTH fragment of up to 36 amino acids are disclosed in WO2011143406.
- longer acting PTH biologics with an increased control over serum calcium levels and reduced side effects are urgently needed to minimise the need for daily subcutaneous injection.
- Recombinant proteins and peptides used in pharmaceuticals often suffer from increased serum clearance.
- Factors that result in the removal of administered proteins from the circulation have two components; renal filtration and proteolysis.
- proteins with a molecular weight above 70 kDa are not cleared by glomerular filtration because they are simply too large to be filtered, however, proteins of small molecular weight are filtered by the glomerulus and are found in the urine.
- a method to increase the effective molecular weight of proteins and to produce a product which has reduced immunogenicity is to coat the protein in polyethylene glycol (PEG).
- PEG is believed to slow renal clearance by providing increased hydrodynamic volume in pegylated proteins (Maxfield et al., Polymer, 16:505-509 (1975)).
- PTH fusion polypeptides wherein PTH fused to a receptor, for example, its cognate receptor and/or GHR have improved PK and PD.
- the PTH fusion polypeptides have utility in the treatment of conditions that result from abnormal PTH activity including hypoparathyroidism and treatment of conditions that benefit from PTH therapy including osteoporosis.
- fusion polypeptide comprising
- Analogue refers to a parathyroid hormone that binds parathyroid hormone receptor or a receptor polypeptide amino acid sequence variant.
- the parathyroid hormone analogue includes but is not limited to amino acid sequences encoding the parathyroid hormone related protein and variants thereof.
- said fusion polypeptide comprises a parathyroid hormone comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 10.
- said fusion polypeptide comprises a fragment of SEQ ID NO: 10 including amino acids 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35.
- said fusion polypeptide comprises a parathyroid hormone comprising the sequence set forth in SEQ ID NO: 9.
- said fusion polypeptide comprises a fragment of SEQ ID NO: 9 including amino acids 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35.
- said fusion polypeptide comprises a parathyroid hormone comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 54.
- said fusion polypeptide comprises a parathyroid hormone analogue comprising or consisting of the amino acid sequence of formula (I):
- said fusion polypeptide comprises a parathyroid hormone and parathyroid hormone analogue amino acid sequence comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 37.
- said fusion polypeptide comprises a parathyroid hormone related protein or biologically active fragment or analogue thereof, comprising the amino acid sequence set forth in SEQ ID NO: 40.
- said fusion polypeptide comprises a fragment of SEQ ID NO: 40 including amino acids 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35.
- said fusion polypeptide comprises a receptor polypeptide comprising a parathyroid hormone receptor extracellular domain.
- said fusion polypeptide comprises a parathyroid hormone receptor extracellular domain comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 3.
- said fusion polypeptide comprises a parathyroid hormone receptor extracellular domain, or fragment thereof, comprising an amino acid sequence, between 10-99% identical to the full length amino acid sequence set forth in SEQ ID NO: 3 and wherein said domain or fragment binds a parathyroid hormone, fragment or analogue thereof.
- said fusion polypeptide comprises a parathyroid hormone receptor extracellular domain or fragment thereof comprising an amino acid sequence that is 10, 15, 20, 30, 40, 50, 60, 70, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to the amino acid sequence set forth in SEQ ID NO: 3 and wherein said domain binds a parathyroid hormone, fragment or analogue thereof.
- said fusion polypeptide comprises a modified amino acid sequence encoding the parathyroid hormone receptor extracellular domain wherein said modification is one or more amino acid substitutions selected from the group consisting of: I107 K, D109A, P104L or L159A as set forth in SEQ ID NO: 3.
- said fusion polypeptide comprises a parathyroid hormone receptor extracellular domain comprising an 107K substitution as set forth in SEQ ID NO: 3.
- said fusion polypeptide comprises a parathyroid hormone comprising or consisting of the amino acid residues 1-14 of the sequence set forth in SEQ ID NO: 10.
- said fusion polypeptide comprises a modified parathyroid hormone receptor extracellular domain wherein said modification is by addition, deletion or substitution of at least one amino acid residue wherein said modified polypeptide substantially lacks parathyroid hormone binding activity or has reduced parathyroid hormone binding activity.
- said fusion polypeptide comprising a receptor polypeptide and alternatively or additionally comprises a growth hormone binding domain polypeptide of growth hormone receptor.
- said fusion polypeptide comprises the extracellular growth hormone binding domain polypeptide of human growth hormone receptor.
- said fusion polypeptide comprises an extracellular growth hormone binding domain polypeptide comprising of the amino acid sequence set forth in SEQ ID NO: 5.
- said fusion polypeptide comprises a modified extracellular growth hormone binding domain polypeptide wherein said modification is by addition, deletion or substitution of at least one amino acid residue wherein said modified polypeptide substantially lacks growth hormone binding activity or has reduced growth hormone binding activity.
- said fusion polypeptide comprises a modification of one or more of the amino acid residues selected from the group consisting of: W169, R43, E44, I103, W104, I105, P106, I164 and D165 as set forth in SEQ ID NO: 5.
- said fusion polypeptide comprises a deletion of amino acid residue tryptophan 104 of the amino acid sequence set forth in SEQ ID NO: 5.
- said fusion polypeptide comprises a substitution of tryptophan 104 of the amino acid sequence as set forth in SEQ ID NO: 5.
- said fusion polypeptide comprises the substitution of tryptophan 104 for alanine as set forth in SEQ ID NO: 7.
- said fusion polypeptide comprises or consists of a parathyroid hormone fragment comprising or consisting of the amino acid residues 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35 of SEQ ID NO: 8.
- said fusion polypeptide comprises a parathyroid hormone or analogue thereof comprising or consisting of the amino acid sequence set forth in SEQ ID Nos: 8, 9 or 10 wherein said parathyroid hormone amino acid sequence is modified by addition, deletion or substitution of at least one amino acid residue and wherein said modified fusion polypeptide retains parathyroid hormone activity.
- said fusion polypeptide comprises a parathyroid hormone or analogue thereof comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 54 wherein said parathyroid hormone amino acid sequence is modified by addition, deletion or substitution of at least one amino acid residue and wherein said modified fusion polypeptide retains parathyroid hormone activity.
- said fusion polypeptide comprises a parathyroid hormone analogue comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 37 or 40 wherein said parathyroid hormone amino acid sequence is modified by addition, deletion or substitution of at least one amino acid residue and wherein said modified fusion polypeptide retains parathyroid hormone activity.
- said fusion polypeptide comprises a modified amino acid sequence that is 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% identical over the full length of the amino acid sequence set forth in SEQ ID NOs: 8, 9 or 10.
- said fusion polypeptide comprises a modified amino acid sequence that is 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% identical over the full length of the amino acid sequence set forth in SEQ ID: NO: 40 or 37.
- said fusion polypeptide comprises a modified amino acid sequence that is 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% identical over the full length of the amino acid sequence set forth in SEQ ID: NO: 54.
- said fusion polypeptide comprises a parathyroid receptor domain polypeptide wherein said parathyroid receptor domain polypeptide is located at the carboxyl-terminal end of said fusion polypeptide.
- said fusion polypeptide comprises a parathyroid receptor domain polypeptide wherein said parathyroid receptor domain polypeptide is located at the amino-terminal end of said fusion polypeptide.
- said fusion polypeptide comprises a growth hormone binding domain polypeptide wherein said growth hormone binding domain polypeptide is located at the carboxyl terminal end of said fusion polypeptide.
- said fusion polypeptide comprises a growth hormone binding domain polypeptide wherein said growth hormone binding domain polypeptide is located at the amino terminal end of said fusion polypeptide.
- said fusion polypeptide comprises or consists of an amino acid sequence set forth in SEQ ID NO: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36.
- said fusion polypeptide comprises or consists of an amino acid sequence set forth in SEQ ID NO: 15 or 20.
- said fusion polypeptide comprises or consists of an amino acid sequence set forth in SEQ ID NO: 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 or 53.
- said fusion polypeptide comprises a pro-peptide.
- said pro-peptide comprises or consists of SEQ ID NO: 11.
- said pro-peptide comprises or consists of SEQ ID NO: 4.
- said fusion polypeptide further comprises a peptide secretion signal.
- said fusion polypeptide comprises a parathyroid hormone peptide secretion signal.
- parathyroid hormone peptide secretion signal comprises the amino acid sequence set forth in SEQ ID NO: 1.
- said fusion polypeptide comprises a parathyroid hormone related protein peptide secretion signal.
- parathyroid hormone related protein peptide secretion signal comprises the amino acid sequence set forth in SEQ ID NO: 41.
- said fusion polypeptide comprises a growth hormone peptide secretion signal.
- said fusion polypeptide comprises a growth hormone secretion signal comprising the amino acid sequence set forth in SEQ ID NO: 2.
- said fusion polypeptide comprises a parathyroid hormone, fragment or analogue thereof and is linked directly or indirectly to said receptor polypeptide by a peptide linker.
- said parathyroid hormone, fragment or analogue is directly linked to said receptor polypeptide as an in-frame translational fusion.
- said peptide linker comprises the amino acid sequence Gly Gly Gly Gly Ser (residues 60-64 of SEQ ID NO: 12).
- said peptide linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 repeat units of a peptide comprising the amino acid sequence Gly Gly Gly Gly Ser (residues 60-64 of SEQ ID NO: 12).
- said peptide linker comprises 4 repeat units of the amino acid sequence Gly Gly Gly Gly Ser (residues 60-64 of SEQ ID NO: 12).
- nucleic acid molecule that encodes a fusion polypeptide according to the invention.
- a vector comprising a nucleic acid molecule according to the invention.
- said vector is an expression vector adapted to express the nucleic acid molecule according to the invention.
- a vector including nucleic acid (s) according to the invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome for stable transfection.
- the nucleic acid in the vector is operably linked to an appropriate promoter or other regulatory elements for transcription in a host cell.
- the vector may be a bi-functional expression vector which functions in multiple hosts.
- promoter is meant a nucleotide sequence upstream from the transcriptional initiation site and which contains all the regulatory regions required for transcription. Suitable promoters include constitutive, tissue-specific, inducible, developmental or other promoters for expression in eukaryotic or prokaryotic cells.
- “Operably linked” means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is “under transcriptional initiation regulation” of the promoter.
- the promoter is a constitutive, an inducible or regulatable promoter.
- a cell transfected or transformed with a nucleic acid molecule or vector according to the invention there is provided a cell transfected or transformed with a nucleic acid molecule or vector according to the invention.
- said cell is a eukaryotic cell.
- said cell is selected from the group consisting of; a fungal cell (e.g. Pichia spp, Saccharomyces spp, Neurospora spp); insect cell (e.g. Spodoptera spp); a mammalian cell (e.g. COS cell, CHO cell); a plant cell.
- a fungal cell e.g. Pichia spp, Saccharomyces spp, Neurospora spp
- insect cell e.g. Spodoptera spp
- a mammalian cell e.g. COS cell, CHO cell
- a plant cell e.g. COS cell, CHO cell
- said cell is a prokaryotic cell.
- a method for the production of the fusion polypeptide according to the invention comprising the steps consisting of:
- composition comprising a fusion polypeptide according to the invention including an excipient or carrier.
- said pharmaceutical composition is combined with a further therapeutic agent.
- compositions of the present invention When administered the pharmaceutical composition of the present invention is administered in pharmaceutically acceptable preparations.
- Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents for example chemotherapeutic agents.
- compositions of the invention can be administered by any conventional route, including injection.
- the administration and application may, for example, be subcutaneous.
- compositions of the invention are administered in effective amounts.
- An “effective amount” is that amount of pharmaceuticals/compositions that alone, or together with further doses or synergistic drugs, produces the desired response. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods.
- the doses of the pharmaceutical compositions administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject (i.e. age, sex).
- the pharmaceutical compositions of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions.
- salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention.
- Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like.
- pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.
- compositions may be combined, if desired, with a pharmaceutically-acceptable carrier.
- pharmaceutically-acceptable carrier as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances that are suitable for administration into a human.
- carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.
- the components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction that would substantially impair the desired pharmaceutical efficacy.
- compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier that constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.
- compositions suitable for subcutaneous administration conveniently comprise a sterile aqueous or non-aqueous preparation that is preferably isotonic with the blood of the recipient.
- This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1, 3-butane diol.
- the acceptable solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or di-glycerides.
- fatty acids such as oleic acid may be used in the preparation of injectables.
- Carrier formulation suitable for subcutaneous administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa.
- a fusion polypeptide according to the invention for use in the treatment of hypoparathyroidism in a subject.
- a method to treat a human subject suffering from hypoparathyroidism comprising administering an effective amount of a fusion polypeptide according to the invention thereby treating hypoparathyroidism.
- a fusion polypeptide according to the invention for use in the treatment of osteoporosis in a human subject.
- a method to treat a human subject suffering from osteoporosis comprising administering an effective amount of a fusion polypeptide according to the invention thereby treating osteoporosis.
- said fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 40.
- said fusion polypeptide is administered in combination with calcium carbonate and/or vitamin D supplements such as calcitrol or alfacalcitrol.
- hypoparathyroidism is caused by thyroid or neck surgery, autoimmune disease, radiotherapy, cancer, Addison's disease or Di-George syndrome.
- said fusion polypeptide is administered at least once a day.
- said fusion polypeptide is administered at least once or twice weekly.
- FIG. 1 We have linked PTH (residues 1-34) to the N-terminal PTH receptor domain (PTHrExt) and the growth hormone binding protein (GHBP).
- GHBP is an inert moiety designed to increase molecular weight and delay clearance. The binding of PTH to PTHrExt protects PTH from degradation and produces a pool of “inactive” PTH that is in equilibrium with active PTH generating a more physiological PTH exposure. Molecules will be expressed under the control of either the PTH secretion signal (with or without the inclusion of the propeptide) or the growth hormone secretion signal to allow for efficient processing in a CHO cell line;
- FIGS. 2A and 2B SDS-PAGE Analysis of Purified Protein.
- FIG. 2A Purified 14A1
- FIG. 2B Purified 14A2b. Proteins were expressed in a CHO cell line and purified as a secreted product from Hyclone SFM4CHO Utility media using a combination of Q-Sepharose and anti-growth hormone receptor affinity chromatography. Protein separates at ⁇ 75-100 kDa and is intact with no sign of degradation;
- FIG. 3 In Vitro Bioactivity of 14A1 and 14A2 proteins. Purified proteins were tested for their ability to stimulate cAMP production from the PTH responsive cell line, UMR-106 (rat osteoblastic like cell line). Cells were stimulated for 15 minutes in the presence of test molecules and cAMP levels measured from cell lysates using a cAMP specific Elisa. Both positive controls, PTH 1-34 (100 ⁇ M), Forskolin (100 ⁇ M) and negative controls (Cells only, Buffer only and Control protein, Erythropoetin) were included in the analysis. Data is presented as pmol cAMP/ml+/ ⁇ Standard deviation;
- FIGS. 4A and 4B Parathyroid Hormone, LOCUS NM_000315 834 bp mRNA linear PRI 13 Jun. 2016, DEFINITION Homo sapiens parathyroid hormone (PTH), transcript variant 1, mRNA., ACCESSION NM_000315, VERSION NM_000315.3, KEYWORDS RefSeq., SOURCE Homo sapiens (human).
- FIG. 4A Signal peptide underlined, propeptide italics/lowercase, mature protein (1-34) shown in uppercase/bold
- FIG. 4B origin, Signal peptide is underlined (116-190 bp), Propeptide in lowercase/italics, Mature protein in uppercase/bold (209-460 bp);
- FIGS. 5A-5D PTH 1-34 used in fusion proteins;
- FIG. 5A Amino acid sequence of PTH 1-34,
- FIG. 5B nucleotide sequence (102 bp),
- FIG. 5C Amino acid sequence of PTH signal peptide and propeptide sequence used in fusion proteins (propeptide in lowercase/italics),
- FIG. 5D Nucleotide sequence of PTH signal peptide and propeptide sequence used in fusion proteins (propeptide in lowercase/italics);
- FIGS. 6A and 6B Human parathyroid hormone receptor 1, FIG. 6A ) LOCUS NM_001184744 2007 bp mRNA linear PRI 6 Oct. 2016, DEFINITION Homo sapiens parathyroid hormone 1 receptor (PTH1R), transcript variant 2, mRNA. ACCESSION NM_001184744 VERSION NM_001184744.1, KEYWORDS RefSeq., SOURCE Homo sapiens (human), Signal peptide underlined, Mature extracellular domain in bold (D29-I187); FIG. 6B ) Signal peptide underlined, Mature extracellular domain in bold;
- FIGS. 7A and 7B PTH receptor extracellular domain used in fusion proteins.
- FIG. 7A Amino acid sequence (aa D29-L187),
- FIG. 7B Nucleotide sequence (477 bp);
- FIGS. 8A and 8B Human growth hormone binding protein (GHBP), FIG. 8A ) GHBP portion of the fusion is composed of amino acid residues 1-238 (extracellular domain) and includes a W104A mutation, Nucleotide sequence of GHBP (714 bp); FIG. 8B ) Amino acid sequence (aa 1-238);
- GHBP Human growth hormone binding protein
- FIGS. 9A and 9B GH Secretion signal, FIG. 9A ) amino acid sequence, FIG. 9B ) nucleotide sequence;
- FIGS. 10A and 10B PTH-(g4s)4-PTHrEx-(g4s)4-GHBP (Code #14A1); PTH Signal peptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): bold/Lowercase, GHBP (aa 1-238): Uppercase; Linker regions (g4s)4: Uppercase/Bold; FIG. 10A ) nucleotide sequence, FIG. 10B ) protein sequence;
- FIGS. 11A and 11B PTH-(g4s)4-PTHrExt-(g4s)4-GHBP (Code #14A2), PTH Signal peptide and propeptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, GHBP (aa 1-238): Uppercase, Linker regions (g4s)4: Uppercase/Bold; FIG. 11A ) nucleotide sequence, FIG. 11B ) protein sequence;
- FIGS. 12A and 12 B PTH-(g4s)4-PTHrExt-(g4s)4-GHBP (Code #14A3), GH Signal peptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, GHBP (aa 1-238): Uppercase, Linker regions (g4s)4: Uppercase/Bold; FIG. 12A ) nucleotide sequence, FIG. 12B ) protein sequence;
- FIGS. 13A and 13B PTH-(g4s)4-GHBP (Code #14A4), GH Signal peptide: Lower case, PTH (aa 1-34): Uppercase/Underlined, GHBP (aa 1-238): Uppercase, Linker region (g4s)4: Uppercase/Bold; FIG. 13A ) nucleotide sequence, FIG. 13B ) protein sequence;
- FIGS. 14A and 14B PTH-(g4s)4-PTHrExt_Hist (Code #14A5_Hist), GH Signal peptide: Lower case, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, Linker region (g4s)4: Uppercase/Bold, C-terminal 6 ⁇ Hist tag: Uppercase/Underlined, FIG. 14A ) nucleotide sequence, FIG. 14B ) protein sequence;
- FIGS. 15A and 15B PTH-(g4s)4-PTHrExt (Code #14A5), GH Signal peptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, Linker region (g4s)4: Uppercase/Bold; FIG. 15A ) nucleotide sequence, FIG. 15B ) protein sequence;
- FIGS. 16A and 16B PTH-(g4s)4-PTHrExt_Hist (Code #14A6_Hist), PTH Signal peptide & propeptide: Lowercase), PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, Linker regions (g4s)4: Uppercase/Bold, C-terminal 6 ⁇ Hist tag: Uppercase/Underlined; FIG. 16A ) nucleotide sequence, FIG. 16B ) protein sequence;
- FIGS. 17A and 17B PTH-(g4s)4-PTHrExt_Hist (Code #14A6), PTH Signal peptide & propeptide: Lower case, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, Linker regions (g4s)4: Uppercase/Bold; FIG. 17A ) nucleotide sequence, FIG. 17B ) protein sequence;
- FIGS. 18A and 18B PTH-(g4s)4-GHBP (Code #14A7), PTH Signal peptide & propeptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, GHBP (aa 1-238): Uppercase, Linker region (g4s)4: Uppercase/Bold; FIG. 18A ) nucleotide sequence, FIG. 18B ) protein sequence;
- FIGS. 19A and 19B PTH-(g4s)4-PTHrExt (I135K)-(g4s)4-GHBP (Code #14A8), PTH Signal peptide & propeptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (I135K) (aa 1-159): Lowercase/Bold (I135K change underlined).
- GHBP (aa 1-238): Uppercase, Linker regions (g4s)4: Uppercase/Bold;
- FIG. 19A nucleotide sequence
- FIG. 19B protein sequence;
- FIGS. 20A and 20B PTH-(g4s)4-GHBP (Code #14A9), GH Signal peptide: Lower case, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (I135K) (aa 1-159): Lowercase/Bold (I135K change underlined), GHBP (aa 1-238): Uppercase, Linker regions (g4s)4: Uppercase/Bold; FIG. 20A ) nucleotide sequence, FIG. 20B ) protein sequence;
- FIGS. 21A and 21B PTH-(g4s)4-PTHrExt (I135K)-Hist (Code #14A10), PTH Signal peptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (I135K) (aa 1-159): Lowercase/Bold (I135K change underlined), Linker region (g4s)4: Uppercase/Bold, C-terminal 6 ⁇ Hist tag: Uppercase/Underlined; FIG. 21A ) nucleotide sequence, FIG. 21B ) protein sequence;
- FIGS. 22A and 22B PTH-(g4s)4-PTHrExt (I135K)-Hist (Code #14A11-Hist), GH Signal peptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (I135K) (aa 1-159): Lowercase/Bold (I135K change underlined), Linker region (g4s)4: Uppercase/Bold, C-terminal 6 ⁇ Hist tag: Uppercase/Underlined; FIG. 22A ) nucleotide sequence, FIG. 22B ) protein sequence;
- FIG. 23 PTH Sequence (AA 1-84);
- FIG. 24 (SEQ ID NO: 40): PTHrP (1-36);
- FIG. 25 (SEQ ID NO: 41): PTHrP signal sequence
- FIG. 26 (SEQ ID NO: 4): PTHrP propeptide
- FIGS. 27A and 27B Schematic models showing the structure of the PTH fusion molecules.
- FIG. 27A PTH (Purple) linked to PTHrExt (Green) which in turn is linked to GHBP (Orange). Linkers shown as grey lines.
- W104A change shown in blue on GHBP. It is hypothesised that a state of equilibrium exists between PTH bound to PTHrExt (Inactive State: A) and PTH being released and able to bind PTHR1 (Active State, B).
- FIG. 27B PTH (Purple) linked to GHBP (Orange). Linker shown as grey line. W104A change shown in blue on GHBP;
- FIGS. 28A, 28B, and 29C Analysis of purified PTH fusion molecules by 10% SDS-PAGE under non-reducing conditions (Coomassie Stained).
- FIG. 28A Lane 1: 5 ⁇ g 14A2c
- Lane 2 5 ⁇ g 14A3b.
- 14A2c (contains PTH prepropeptide) separates as two diffuse bands from 60-100 kDa.
- 14A3b (GHss) resolves as a single diffuse band ⁇ 75-100 kDa.
- FIG. 28B Lane 3: 6 ⁇ g 14A7
- Lane 4 3 ⁇ g 14A4. Proteins judged to be >90% pure. Obtained ⁇ 10 mg 14A2c, ⁇ 4 mg 14A3b, 1.42 mg 14A7 and 0.29 mg 14A4 purified protein from a 1 litre roller bottle culture.
- FIG. 28C Western blot anti PTH 14A2c & 14A3b. Analysis of purified PTH fusion molecules by 10% SDS-PAGE under non-reducing conditions. Samples were transferred to a PVDF membrane and probed with anti-human PTH (1-34) specific antibody. Lanes 1-3: 14A2c at a loading of 125 ng, 250 ng and 500 ng. Lanes 4-6: 14A3b at a loading of 125 ng, 250 ng and 500 ng. 14A2c is more sensitive to detection by anti-PTH antibody. Representative of 3 independent western blot experiments;
- FIG. 29A In vitro induction of cAMP.
- UMR-106 cells were challenged with either 500 nM PTH fusion or 100 nM human PTH 1-34 for 15 minutes at 3TC/5% CO 2 .
- Cells were lysed and cAMP levels measured using an R & D systems Parameter cAMP Elisa. Data are presented as log pmol cAMP/ml ⁇ SD.
- An 11-fold increase in cAMP levels was found for 14A2c over 14A3b: mean ⁇ SD 264 ⁇ 12 vs 25 ⁇ 0.95 pmol cAMP/ml.
- FIG. 29B Dual Luciferase Reporter Assay for cAMP Activity.
- UMR-106 cells were transfected with the reporter plasmid pGL4.29/CRE/Luc2/Hygro and transfection control plasmid phRL (Renilla) and challenged with either PTH fusion or human PTH 1-34 for 5 hours at 3TC/5% CO 2 .
- Cells were lysed and Luciferase activity measured using the Promega Dual Luciferase Assay kit. Data are presented as fold induction of control ⁇ SD.
- 14A2c is more bioactive than 14A3b equating to a ⁇ 1.3 to 1.6 fold increase at 100 & 500 nM respectively: mean fold induction ⁇ SD, 16.5 ⁇ 1.7, 63 ⁇ 5.9 vs 12.4 ⁇ 1.0, 40.3 ⁇ 3.1. Average of triplicate values. Both Fusions showed reduced biological activity when compared to PTH 1-34 at an equivalent concentration of 100 nM: mean ⁇ SD, 67.3 ⁇ 1.6. Representative of 3 separate experiments.
- FIG. 29C Dual Luciferase Reporter Assay for cAMP Activity Comparison of all 4 PTH fusion molecules.
- UMR-106 cells were transfected with the reporter plasmid pGL4.29/CRE/Luc2/Hygro and transfection control plasmid phRL (Renilla) and challenged with either PTH fusion or human PTH 1-34 for 5 hours at 37° C./5% CO 2 .
- Cells were lysed and Luciferase activity measured using the Promega Dual Luciferase Assay kit. Data are presented as fold induction of control ⁇ SD. Pattern of activity is similar to previous assays for 14A2c & 14A3b vs PTH.
- Both PTH-GHBP fusion molecules (14A4, 49 ⁇ 4.17 & 14A7, 44 ⁇ 0.42) are more active than the PTH-PTHrExt-GHBP fusion molecules (14A2c, 15 ⁇ 0.09 & 14A3b, 7.7 ⁇ 3.13) at 100 nM. At 100 nM both 14A4 and 14A7 have comparable activity to PTH (54 ⁇ 2.7).
- FIG. 29D Determination of EC 50 values for PTH & PTH fusions using the Dual Luciferase Reporter Assay.
- Sequence Listing is submitted as an ASCII text file in the form of the file name “Sequence.txt,” 163,840 bytes, created on Mar. 18, 2022, which is incorporated by reference herein.
- Linker regions in the above fusions are composed of multiples of GGGGS.
- the linker regions are composed of 4 ⁇ GGGGS (residues 66-85 of SEQ ID NO: 20), but variable multiples can be used.
- the I135K change present in PTHrExt in selected constructs has been shown to reduce the binding of PTH for the receptor.
- Other amino acid changes can also be used in combination or as single point mutations such as D137A, P132L & L187A. (SEQ ID NO: 56).
- PTH fusions Molecules were constructed by a combination of gene synthesis (Eurofin MWG) and standard DNA manipulation techniques. Recombinant genes encoding full length PTH fusions were cloned into a modified mammalian expression plasmid, pSecTag/FRT/V5/Hist-TOPO (Invitrogen). Stable cell lines were produced in the CHO Flp-In cell line (Invitrogen) according to manufacturer's instructions and adapted to serum free media in Hyclone SFM4CHO Utility (Thermo Scientific). PTH fusions were under the secreted expression of either the PTH or GH signal peptides.
- EDTA and Benzamidine-HCl were added to final concentrations of 5 and 10 mM respectively and the medium concentrated using a Vivaflow 200 tangential flow concentrator and stored frozen at ⁇ 20° C.
- Target protein was purified from this concentrate by anion exchange (Q-Sepharose FF, GE Healthcare) and affinity chromatography (anti GHBP antibody column). Protein concentrations were measured by Bradford protein assay and samples analysed by SDS-PAGE under non-reducing conditions and either stained with coomassie blue or western blotted using a commercial anti-PTH 1-34 antibody (Abcam 14493) or an in house developed anti GHBP antibody. Purified samples were aliquoted and stored at ⁇ 80° C.
- TPTX thyroparathyroidectomized
- the PTH is shown to sit in a groove formed by the N-terminal receptor portion. It is this mode of interaction that is hypothesised to protect PTH from degradation and to create an “inactive pool” of PTH, thus prolonging its biological activity to create a long acting PTH. It is proposed that the new molecules (See FIG. 1 ) will be fusions between PTH (residues 1-34), the N-terminal PTH receptor domain (PTHrExt, most commonly residues D29-L187 but not restricted to other combinations) and the growth hormone binding protein (GHBP, residues 1-238). GHBP is an inert moiety designed to increase Mw & therefore delay clearance. It will contain a W104A mutation to prevent interaction with GH in the circulation.
- PTH1-34 has been fused to growth hormone binding protein (GHbp) with or without the extracellular domain of the PTH receptor (PTHextR). Molecules have then been expressed with either the GH (GHss) or PTH (PTHss) signal sequence and propeptide (pp). Thus, the following 4 molecules have been generated:
- Parathyroid hormone is an 84-aa peptide with biological activity residing in residues 1-34. PTH is produced by the parathyroid glands in response to low serum calcium levels. PTH acts on the parathyroid receptor (PTHR1) on bone and kidney promoting the release of calcium from bone, slowing excretion of calcium from kidneys, increasing absorption from intestines and promoting renal excretion of phosphate. In Hypoparathyroidism (HypoPT) the parathyroid glands are either absent or damaged and therefore cannot produce any or sufficient amounts of parathyroid hormone. Initial treatment is with oral calcium and active VD3 supplements.
- PTH will form intramolecular interactions with PTHrExt, be protected from degradation, and provide an intravascular pool of active PTH.
- PTHrExt a single amino acid change of tryptophan-104 to alanine in the GHBP moiety (W104A) will be introduced in to all PTH fusion molecules. All PTH fusion will be expressed using either the naturally occurring PTH prepropeptide sequence or the GH secretion signal.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The disclosure relates to long acting parathyroid or parathyroid hormone like fusion polypeptides comprising a receptor polypeptide and its use in the treatment of hypoparathyroidism and osteoporosis.
Description
- This is a continuation of U.S. Ser. No. 16/608,611, filed on Oct. 25, 2019, which is the U.S. National Stage of International Application No. PCT/GB2018/051120, filed Apr. 27, 2018, which was published in English under PCT Article 21(2), which in turn claims the benefit of Great Britain Application No. 1706781.0, filed Apr. 28, 2017.
- The disclosure relates to long acting parathyroid hormone fusion polypeptides comprising a receptor polypeptide wherein the receptor polypeptide is a parathyroid hormone receptor and/or growth hormone receptor; nucleic acid molecules encoding said fusion polypeptides; vectors adapted to express said fusion polypeptides; cells transformed or transfected with said nucleic acids or vectors; and use of said polypeptides in the treatment of hypoparathyroidism.
- Hypoparathyroidism, characterised by low parathyroid hormone (PTH) levels, is a rare condition and is either congenital or more often acquired following surgery to the neck. PTH is secreted by the four parathyroid glands which are located next to the thyroid gland in the neck and controls calcium homeostasis, vitamin D-dependent calcium absorption, renal calcium reabsorption and renal phosphate clearance. PTH stimulates the release of calcium from the bone and enhances absorption of calcium in the intestine. Reduced PTH levels lead to hypocalcaemia and include symptoms such as neuromuscular irritability, including paraesthesia, muscle twitching, laryngeal spasms, tetany and seizures and can lead, if untreated to death.
- Current standard therapy is high dose calcium and active vitamin D; however, many patients show despite treatment fluctuating calcium levels, an increased incidence of depression as well as an increased risk of infections and renal complications such as calcifications and renal insufficiency. PTH is an 84-amino acid long polypeptide comprising a 34 long amino acid N-terminal biologically active domain which was found to be an effective PTH receptor agonist.
- Currently recombinant PTH is administered as a daily subcutaneous injection. PTH is known to be unstable in vitro and has a short half-life in vivo resulting in fluctuating PTH levels which are associated with nausea and vomiting. Compositions stabilising PTH in vitro are disclosed in U.S. Pat. Nos. 7,550,434, 7,144,861, 6,770,623, WO2006/129995 or WO2013/108235, and recombinant PTH analogues with enhanced pharmacokinetics and pharmacodynamics comprising a modified PTH fragment of up to 36 amino acids are disclosed in WO2011143406. However, longer acting PTH biologics with an increased control over serum calcium levels and reduced side effects are urgently needed to minimise the need for daily subcutaneous injection.
- Recombinant proteins and peptides used in pharmaceuticals often suffer from increased serum clearance. Factors that result in the removal of administered proteins from the circulation have two components; renal filtration and proteolysis. Typically, proteins with a molecular weight above 70 kDa are not cleared by glomerular filtration because they are simply too large to be filtered, however, proteins of small molecular weight are filtered by the glomerulus and are found in the urine. A method to increase the effective molecular weight of proteins and to produce a product which has reduced immunogenicity is to coat the protein in polyethylene glycol (PEG). PEG is believed to slow renal clearance by providing increased hydrodynamic volume in pegylated proteins (Maxfield et al., Polymer, 16:505-509 (1975)). However, pegylation of proteins can result in decreased affinity for its receptor reducing the biological activity. An alternative means to improved PK and PD of protein biologics is disclosed in WO2009/013461. Human growth hormone fused to an extracellular domain of human growth hormone receptor (GHR) have enhanced PK and PD improving PK by approximately 200-fold when compared to growth hormone. In PCT/GB2016/053218, currently unpublished, the effect of GHR on non-growth hormone polypeptides is disclosed wherein leptin and granulocyte colony stimulating factor (GSCF) when fused to GHR have improved PK and PD.
- This disclosure relates to PTH fusion polypeptides wherein PTH fused to a receptor, for example, its cognate receptor and/or GHR have improved PK and PD. The PTH fusion polypeptides have utility in the treatment of conditions that result from abnormal PTH activity including hypoparathyroidism and treatment of conditions that benefit from PTH therapy including osteoporosis.
- According to an aspect of the invention there is provided a fusion polypeptide comprising
-
- a polypeptide comprising an amino acid sequence of a parathyroid hormone or biologically active fragment or analogue thereof,
- a polypeptide comprising an amino acid sequence of a receptor polypeptide or fragment or analogue thereof wherein said parathyroid hormone or biologically active fragment or analogue thereof is linked either directly or indirectly as a translational fusion to said receptor polypeptide.
- “Analogue” refers to a parathyroid hormone that binds parathyroid hormone receptor or a receptor polypeptide amino acid sequence variant. The parathyroid hormone analogue includes but is not limited to amino acid sequences encoding the parathyroid hormone related protein and variants thereof.
- In a preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 10.
- In a preferred embodiment of the invention said fusion polypeptide comprises a fragment of SEQ ID NO: 10 including amino acids 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35.
- In a preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone comprising the sequence set forth in SEQ ID NO: 9.
- In a preferred embodiment of the invention said fusion polypeptide comprises a fragment of SEQ ID NO: 9 including amino acids 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35.
- In a preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 54.
- In a preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone analogue comprising or consisting of the amino acid sequence of formula (I):
-
(SEQ ID NO: 8) Xaa01-Val-Xaa03-Glu-Ile-Gln-Leu-Xaa08-His-Xaa10- Xaa11-Xaa12-Xaa13-Xaa14-Leu-Xaa16-Xaa17-Xaa18-Arg- Arg-Arg-Xaa22-Phe-Leu-Xaa25-Xaa26-Leu-Ile-Ala-Glu- Ile-His-Thr-Ala-Glu-Ile -
- (I) where Xaa01 is Ser or Ala; Xaa03 is Ser or Ala; Xaa08 is Met or Leu; Xaa10 is Asn, Ala, Val, Asp, Glu, or Gln; Xaa11 is Leu, Ala, Val, Met, Lys, Arg, or Trp; Xaa12 is Gly, Ala, His, or Arg; Xaa13 is Lys, Ala, Leu, Gln, Arg, His, or Trp; Xaa14 is His, Leu, Arg, Phe, Trp, or Ser; Xaa16 is Gln or Asn; Xaa17 is Asp or Ser; Xaa18 is Ala, Leu, Met, Glu, Ser, or Phe; Xaa22 is Ala, Phe, Glu, Ser, Leu, Asn, Trp, or Lys; Xaa25 is His, Arg, Leu, Trp, or Lys; and Xaa26 is Lys, His, Ala, Ser, Asn, or Arg or a fragment thereof including amino acids 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35 of formula (I), with the proviso that at least one of Xaa18 is not Leu or Met, Xaa22 is not Phe, and Xaa26 is not His.
- In a preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone and parathyroid hormone analogue amino acid sequence comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 37.
- In an alternative embodiment of the invention said fusion polypeptide comprises a parathyroid hormone related protein or biologically active fragment or analogue thereof, comprising the amino acid sequence set forth in SEQ ID NO: 40.
- In a preferred embodiment of the invention said fusion polypeptide comprises a fragment of SEQ ID NO: 40 including amino acids 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35.
- In a preferred embodiment of the invention said fusion polypeptide comprises a receptor polypeptide comprising a parathyroid hormone receptor extracellular domain.
- In a preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone receptor extracellular domain comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 3.
- In a further preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone receptor extracellular domain, or fragment thereof, comprising an amino acid sequence, between 10-99% identical to the full length amino acid sequence set forth in SEQ ID NO: 3 and wherein said domain or fragment binds a parathyroid hormone, fragment or analogue thereof.
- In a further preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone receptor extracellular domain or fragment thereof comprising an amino acid sequence that is 10, 15, 20, 30, 40, 50, 60, 70, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% identical to the amino acid sequence set forth in SEQ ID NO: 3 and wherein said domain binds a parathyroid hormone, fragment or analogue thereof.
- In a preferred embodiment of the invention said fusion polypeptide comprises a modified amino acid sequence encoding the parathyroid hormone receptor extracellular domain wherein said modification is one or more amino acid substitutions selected from the group consisting of: I107 K, D109A, P104L or L159A as set forth in SEQ ID NO: 3.
- In a further preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone receptor extracellular domain comprising an 107K substitution as set forth in SEQ ID NO: 3.
- In a preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone comprising or consisting of the amino acid residues 1-14 of the sequence set forth in SEQ ID NO: 10.
- In an alternative embodiment of the invention said fusion polypeptide comprises a modified parathyroid hormone receptor extracellular domain wherein said modification is by addition, deletion or substitution of at least one amino acid residue wherein said modified polypeptide substantially lacks parathyroid hormone binding activity or has reduced parathyroid hormone binding activity.
- In an embodiment of the invention said fusion polypeptide comprising a receptor polypeptide and alternatively or additionally comprises a growth hormone binding domain polypeptide of growth hormone receptor.
- In a preferred embodiment of the invention said fusion polypeptide comprises the extracellular growth hormone binding domain polypeptide of human growth hormone receptor.
- In a further embodiment of the invention said fusion polypeptide comprises an extracellular growth hormone binding domain polypeptide comprising of the amino acid sequence set forth in SEQ ID NO: 5.
- In an alternative embodiment of the invention said fusion polypeptide comprises a modified extracellular growth hormone binding domain polypeptide wherein said modification is by addition, deletion or substitution of at least one amino acid residue wherein said modified polypeptide substantially lacks growth hormone binding activity or has reduced growth hormone binding activity.
- In a preferred embodiment of the invention said fusion polypeptide comprises a modification of one or more of the amino acid residues selected from the group consisting of: W169, R43, E44, I103, W104, I105, P106, I164 and D165 as set forth in SEQ ID NO: 5.
- In a preferred embodiment of the invention said fusion polypeptide comprises a deletion of amino acid residue tryptophan 104 of the amino acid sequence set forth in SEQ ID NO: 5.
- In an alternative embodiment of the invention said fusion polypeptide comprises a substitution of tryptophan 104 of the amino acid sequence as set forth in SEQ ID NO: 5.
- In a preferred embodiment of the invention said fusion polypeptide comprises the substitution of tryptophan 104 for alanine as set forth in SEQ ID NO: 7.
- In a further preferred embodiment of the invention said fusion polypeptide comprises or consists of a parathyroid hormone fragment comprising or consisting of the amino acid residues 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35 of SEQ ID NO: 8.
- In a further preferred embodiment said fusion polypeptide comprises a parathyroid hormone or analogue thereof comprising or consisting of the amino acid sequence set forth in SEQ ID Nos: 8, 9 or 10 wherein said parathyroid hormone amino acid sequence is modified by addition, deletion or substitution of at least one amino acid residue and wherein said modified fusion polypeptide retains parathyroid hormone activity.
- In a further preferred embodiment said fusion polypeptide comprises a parathyroid hormone or analogue thereof comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 54 wherein said parathyroid hormone amino acid sequence is modified by addition, deletion or substitution of at least one amino acid residue and wherein said modified fusion polypeptide retains parathyroid hormone activity.
- In a further preferred embodiment said fusion polypeptide comprises a parathyroid hormone analogue comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 37 or 40 wherein said parathyroid hormone amino acid sequence is modified by addition, deletion or substitution of at least one amino acid residue and wherein said modified fusion polypeptide retains parathyroid hormone activity.
- In a further preferred embodiment said fusion polypeptide comprises a modified amino acid sequence that is 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% identical over the full length of the amino acid sequence set forth in SEQ ID NOs: 8, 9 or 10.
- In a further preferred embodiment said fusion polypeptide comprises a modified amino acid sequence that is 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% identical over the full length of the amino acid sequence set forth in SEQ ID: NO: 40 or 37.
- In a further preferred embodiment said fusion polypeptide comprises a modified amino acid sequence that is 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% identical over the full length of the amino acid sequence set forth in SEQ ID: NO: 54.
- In a preferred embodiment of the invention said fusion polypeptide comprises a parathyroid receptor domain polypeptide wherein said parathyroid receptor domain polypeptide is located at the carboxyl-terminal end of said fusion polypeptide.
- In an alternative embodiment of the invention said fusion polypeptide comprises a parathyroid receptor domain polypeptide wherein said parathyroid receptor domain polypeptide is located at the amino-terminal end of said fusion polypeptide.
- In an alternative embodiment of the invention said fusion polypeptide comprises a growth hormone binding domain polypeptide wherein said growth hormone binding domain polypeptide is located at the carboxyl terminal end of said fusion polypeptide.
- In an embodiment of the invention said fusion polypeptide comprises a growth hormone binding domain polypeptide wherein said growth hormone binding domain polypeptide is located at the amino terminal end of said fusion polypeptide.
- In a preferred embodiment of the invention said fusion polypeptide comprises or consists of an amino acid sequence set forth in SEQ ID NO: 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35 or 36.
- In a preferred embodiment of the invention said fusion polypeptide comprises or consists of an amino acid sequence set forth in SEQ ID NO: 15 or 20.
- In a preferred embodiment of the invention said fusion polypeptide comprises or consists of an amino acid sequence set forth in SEQ ID NO: 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 or 53.
- In a preferred embodiment of the invention said fusion polypeptide comprises a pro-peptide.
- In a further preferred embodiment of the invention said pro-peptide comprises or consists of SEQ ID NO: 11.
- In an alternative preferred embodiment of the invention said pro-peptide comprises or consists of SEQ ID NO: 4.
- In a preferred embodiment of the invention said fusion polypeptide further comprises a peptide secretion signal.
- In a preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone peptide secretion signal.
- In a preferred embodiment of the invention said parathyroid hormone peptide secretion signal comprises the amino acid sequence set forth in SEQ ID NO: 1.
- In a preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone related protein peptide secretion signal.
- In a preferred embodiment of the invention said parathyroid hormone related protein peptide secretion signal comprises the amino acid sequence set forth in SEQ ID NO: 41.
- In an alternative preferred embodiment of the invention said fusion polypeptide comprises a growth hormone peptide secretion signal.
- In a preferred embodiment of the invention said fusion polypeptide comprises a growth hormone secretion signal comprising the amino acid sequence set forth in SEQ ID NO: 2.
- In a preferred embodiment of the invention said fusion polypeptide comprises a parathyroid hormone, fragment or analogue thereof and is linked directly or indirectly to said receptor polypeptide by a peptide linker.
- In an alternative embodiment of the invention said parathyroid hormone, fragment or analogue is directly linked to said receptor polypeptide as an in-frame translational fusion.
- Preferably said peptide linker comprises the amino acid sequence Gly Gly Gly Gly Ser (residues 60-64 of SEQ ID NO: 12).
- In a further preferred embodiment said peptide linker comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 repeat units of a peptide comprising the amino acid sequence Gly Gly Gly Gly Ser (residues 60-64 of SEQ ID NO: 12).
- In a further preferred embodiment said peptide linker comprises 4 repeat units of the amino acid sequence Gly Gly Gly Gly Ser (residues 60-64 of SEQ ID NO: 12).
- According to a further aspect of the invention there is provided a nucleic acid molecule that encodes a fusion polypeptide according to the invention.
- According to a further aspect of the invention there is provided a vector comprising a nucleic acid molecule according to the invention.
- In a preferred embodiment of the invention said vector is an expression vector adapted to express the nucleic acid molecule according to the invention.
- A vector including nucleic acid (s) according to the invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome for stable transfection. Preferably the nucleic acid in the vector is operably linked to an appropriate promoter or other regulatory elements for transcription in a host cell. The vector may be a bi-functional expression vector which functions in multiple hosts. By “promoter” is meant a nucleotide sequence upstream from the transcriptional initiation site and which contains all the regulatory regions required for transcription. Suitable promoters include constitutive, tissue-specific, inducible, developmental or other promoters for expression in eukaryotic or prokaryotic cells. “Operably linked” means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is “under transcriptional initiation regulation” of the promoter.
- In a preferred embodiment the promoter is a constitutive, an inducible or regulatable promoter.
- According to a further aspect of the invention there is provided a cell transfected or transformed with a nucleic acid molecule or vector according to the invention.
- Preferably said cell is a eukaryotic cell.
- In a preferred embodiment of the invention said cell is selected from the group consisting of; a fungal cell (e.g. Pichia spp, Saccharomyces spp, Neurospora spp); insect cell (e.g. Spodoptera spp); a mammalian cell (e.g. COS cell, CHO cell); a plant cell.
- In an alternative embodiment of the invention said cell is a prokaryotic cell.
- According to an aspect of the invention there is provided a method for the production of the fusion polypeptide according to the invention comprising the steps consisting of:
-
- i) providing a cell according to the invention and cell culture medium;
- ii) culturing said cell; and
- iii) isolating from said cell or medium a fusion polypeptide according to the invention.
- According to a further aspect of the invention there is provided a pharmaceutical composition comprising a fusion polypeptide according to the invention including an excipient or carrier.
- In a preferred embodiment of the invention said pharmaceutical composition is combined with a further therapeutic agent.
- When administered the pharmaceutical composition of the present invention is administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, and optionally other therapeutic agents for example chemotherapeutic agents.
- The pharmaceutical compositions of the invention can be administered by any conventional route, including injection. The administration and application may, for example, be subcutaneous.
- Pharmaceutical compositions of the invention are administered in effective amounts. An “effective amount” is that amount of pharmaceuticals/compositions that alone, or together with further doses or synergistic drugs, produces the desired response. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. This can be monitored by routine methods or can be monitored according to diagnostic methods.
- The doses of the pharmaceutical compositions administered to a subject can be chosen in accordance with different parameters, in particular in accordance with the mode of administration used and the state of the subject (i.e. age, sex). When administered, the pharmaceutical compositions of the invention are applied in pharmaceutically-acceptable amounts and in pharmaceutically-acceptable compositions. When used in medicine salts should be pharmaceutically acceptable, but non-pharmaceutically acceptable salts may conveniently be used to prepare pharmaceutically-acceptable salts thereof and are not excluded from the scope of the invention. Such pharmacologically and pharmaceutically-acceptable salts include, but are not limited to, those prepared from the following acids: hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, maleic, acetic, salicylic, citric, formic, malonic, succinic, and the like. Also, pharmaceutically-acceptable salts can be prepared as alkaline metal or alkaline earth salts, such as sodium, potassium or calcium salts.
- The pharmaceutical compositions may be combined, if desired, with a pharmaceutically-acceptable carrier. The term “pharmaceutically-acceptable carrier” as used herein means one or more compatible solid or liquid fillers, diluents or encapsulating substances that are suitable for administration into a human. The term “carrier” denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The components of the pharmaceutical compositions also are capable of being co-mingled with the molecules of the present invention, and with each other, in a manner such that there is no interaction that would substantially impair the desired pharmaceutical efficacy.
- The pharmaceutical compositions may contain suitable buffering agents, including: acetic acid in a salt; citric acid in a salt; boric acid in a salt; and phosphoric acid in a salt. The pharmaceutical compositions also may contain, optionally, suitable preservatives, such as: benzalkonium chloride; chlorobutanol; parabens and thimerosal.
- The pharmaceutical compositions may conveniently be presented in unit dosage form and may be prepared by any of the methods well-known in the art of pharmacy. All methods include the step of bringing the active agent into association with a carrier that constitutes one or more accessory ingredients. In general, the compositions are prepared by uniformly and intimately bringing the active compound into association with a liquid carrier, a finely divided solid carrier, or both, and then, if necessary, shaping the product.
- Compositions suitable for subcutaneous administration conveniently comprise a sterile aqueous or non-aqueous preparation that is preferably isotonic with the blood of the recipient. This preparation may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation also may be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1, 3-butane diol. Among the acceptable solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid may be used in the preparation of injectables. Carrier formulation suitable for subcutaneous administrations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pa.
- According to an aspect of the invention there is provided a fusion polypeptide according to the invention for use in the treatment of hypoparathyroidism in a subject.
- According to a further aspect of the invention there is provided a method to treat a human subject suffering from hypoparathyroidism comprising administering an effective amount of a fusion polypeptide according to the invention thereby treating hypoparathyroidism.
- According to an aspect of the invention there is provided a fusion polypeptide according to the invention for use in the treatment of osteoporosis in a human subject.
- According to a further aspect of the invention there is provided a method to treat a human subject suffering from osteoporosis comprising administering an effective amount of a fusion polypeptide according to the invention thereby treating osteoporosis.
- In a preferred embodiment or method of the invention said fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 40.
- In a preferred embodiment or method of the invention said fusion polypeptide is administered in combination with calcium carbonate and/or vitamin D supplements such as calcitrol or alfacalcitrol.
- In a preferred embodiment or method of the invention said hypoparathyroidism is caused by thyroid or neck surgery, autoimmune disease, radiotherapy, cancer, Addison's disease or Di-George syndrome.
- In a preferred embodiment or method of the invention said fusion polypeptide is administered at least once a day.
- In an embodiment or method of the invention said fusion polypeptide is administered at least once or twice weekly.
- Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of the words, for example “comprising” and “comprises”, means “including but not limited to”, and is not intended to (and does not) exclude other moieties, additives, components, integers or steps.
- Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.
- Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.
- An embodiment of the invention will now be described by example only and with reference to the following figures:
-
FIG. 1 : We have linked PTH (residues 1-34) to the N-terminal PTH receptor domain (PTHrExt) and the growth hormone binding protein (GHBP). GHBP is an inert moiety designed to increase molecular weight and delay clearance. The binding of PTH to PTHrExt protects PTH from degradation and produces a pool of “inactive” PTH that is in equilibrium with active PTH generating a more physiological PTH exposure. Molecules will be expressed under the control of either the PTH secretion signal (with or without the inclusion of the propeptide) or the growth hormone secretion signal to allow for efficient processing in a CHO cell line; -
FIGS. 2A and 2B : SDS-PAGE Analysis of Purified Protein.FIG. 2A ) Purified 14A1,FIG. 2B ) Purified 14A2b. Proteins were expressed in a CHO cell line and purified as a secreted product from Hyclone SFM4CHO Utility media using a combination of Q-Sepharose and anti-growth hormone receptor affinity chromatography. Protein separates at ˜75-100 kDa and is intact with no sign of degradation; -
FIG. 3 : In Vitro Bioactivity of 14A1 and 14A2 proteins. Purified proteins were tested for their ability to stimulate cAMP production from the PTH responsive cell line, UMR-106 (rat osteoblastic like cell line). Cells were stimulated for 15 minutes in the presence of test molecules and cAMP levels measured from cell lysates using a cAMP specific Elisa. Both positive controls, PTH 1-34 (100 μM), Forskolin (100 μM) and negative controls (Cells only, Buffer only and Control protein, Erythropoetin) were included in the analysis. Data is presented as pmol cAMP/ml+/−Standard deviation; -
FIGS. 4A and 4B : Parathyroid Hormone, LOCUS NM_000315 834 bp mRNAlinear PRI 13 Jun. 2016, DEFINITION Homo sapiens parathyroid hormone (PTH),transcript variant 1, mRNA., ACCESSION NM_000315, VERSION NM_000315.3, KEYWORDS RefSeq., SOURCE Homo sapiens (human).FIG. 4A ) Signal peptide underlined, propeptide italics/lowercase, mature protein (1-34) shown in uppercase/bold,FIG. 4B ) origin, Signal peptide is underlined (116-190 bp), Propeptide in lowercase/italics, Mature protein in uppercase/bold (209-460 bp); -
FIGS. 5A-5D : PTH 1-34 used in fusion proteins;FIG. 5A ) Amino acid sequence of PTH 1-34,FIG. 5B ) nucleotide sequence (102 bp),FIG. 5C ) Amino acid sequence of PTH signal peptide and propeptide sequence used in fusion proteins (propeptide in lowercase/italics),FIG. 5D ) Nucleotide sequence of PTH signal peptide and propeptide sequence used in fusion proteins (propeptide in lowercase/italics); -
FIGS. 6A and 6B : Humanparathyroid hormone receptor 1,FIG. 6A ) LOCUS NM_001184744 2007 bp mRNAlinear PRI 6 Oct. 2016, DEFINITION Homo sapiensparathyroid hormone 1 receptor (PTH1R),transcript variant 2, mRNA. ACCESSION NM_001184744 VERSION NM_001184744.1, KEYWORDS RefSeq., SOURCE Homo sapiens (human), Signal peptide underlined, Mature extracellular domain in bold (D29-I187);FIG. 6B ) Signal peptide underlined, Mature extracellular domain in bold; -
FIGS. 7A and 7B : PTH receptor extracellular domain used in fusion proteins.FIG. 7A ) Amino acid sequence (aa D29-L187),FIG. 7B ) Nucleotide sequence (477 bp); -
FIGS. 8A and 8B : Human growth hormone binding protein (GHBP),FIG. 8A ) GHBP portion of the fusion is composed of amino acid residues 1-238 (extracellular domain) and includes a W104A mutation, Nucleotide sequence of GHBP (714 bp);FIG. 8B ) Amino acid sequence (aa 1-238); -
FIGS. 9A and 9B : GH Secretion signal,FIG. 9A ) amino acid sequence,FIG. 9B ) nucleotide sequence; -
FIGS. 10A and 10B : PTH-(g4s)4-PTHrEx-(g4s)4-GHBP (Code #14A1); PTH Signal peptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): bold/Lowercase, GHBP (aa 1-238): Uppercase; Linker regions (g4s)4: Uppercase/Bold;FIG. 10A ) nucleotide sequence,FIG. 10B ) protein sequence; -
FIGS. 11A and 11B : PTH-(g4s)4-PTHrExt-(g4s)4-GHBP (Code #14A2), PTH Signal peptide and propeptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, GHBP (aa 1-238): Uppercase, Linker regions (g4s)4: Uppercase/Bold;FIG. 11A ) nucleotide sequence,FIG. 11B ) protein sequence; -
FIGS. 12A and 12 B: PTH-(g4s)4-PTHrExt-(g4s)4-GHBP (Code #14A3), GH Signal peptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, GHBP (aa 1-238): Uppercase, Linker regions (g4s)4: Uppercase/Bold;FIG. 12A ) nucleotide sequence,FIG. 12B ) protein sequence; -
FIGS. 13A and 13B : PTH-(g4s)4-GHBP (Code #14A4), GH Signal peptide: Lower case, PTH (aa 1-34): Uppercase/Underlined, GHBP (aa 1-238): Uppercase, Linker region (g4s)4: Uppercase/Bold;FIG. 13A ) nucleotide sequence,FIG. 13B ) protein sequence; -
FIGS. 14A and 14B : PTH-(g4s)4-PTHrExt_Hist (Code #14A5_Hist), GH Signal peptide: Lower case, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, Linker region (g4s)4: Uppercase/Bold, C-terminal 6× Hist tag: Uppercase/Underlined,FIG. 14A ) nucleotide sequence,FIG. 14B ) protein sequence; -
FIGS. 15A and 15B : PTH-(g4s)4-PTHrExt (Code #14A5), GH Signal peptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, Linker region (g4s)4: Uppercase/Bold;FIG. 15A ) nucleotide sequence,FIG. 15B ) protein sequence; -
FIGS. 16A and 16B : PTH-(g4s)4-PTHrExt_Hist (Code #14A6_Hist), PTH Signal peptide & propeptide: Lowercase), PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, Linker regions (g4s)4: Uppercase/Bold, C-terminal 6× Hist tag: Uppercase/Underlined;FIG. 16A ) nucleotide sequence,FIG. 16B ) protein sequence; -
FIGS. 17A and 17B : PTH-(g4s)4-PTHrExt_Hist (Code #14A6), PTH Signal peptide & propeptide: Lower case, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (aa 1-159): Lowercase/Bold, Linker regions (g4s)4: Uppercase/Bold;FIG. 17A ) nucleotide sequence,FIG. 17B ) protein sequence; -
FIGS. 18A and 18B : PTH-(g4s)4-GHBP (Code #14A7), PTH Signal peptide & propeptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, GHBP (aa 1-238): Uppercase, Linker region (g4s)4: Uppercase/Bold;FIG. 18A ) nucleotide sequence,FIG. 18B ) protein sequence; -
FIGS. 19A and 19B : PTH-(g4s)4-PTHrExt (I135K)-(g4s)4-GHBP (Code #14A8), PTH Signal peptide & propeptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (I135K) (aa 1-159): Lowercase/Bold (I135K change underlined). GHBP (aa 1-238): Uppercase, Linker regions (g4s)4: Uppercase/Bold;FIG. 19A ) nucleotide sequence,FIG. 19B ) protein sequence; -
FIGS. 20A and 20B : PTH-(g4s)4-GHBP (Code #14A9), GH Signal peptide: Lower case, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (I135K) (aa 1-159): Lowercase/Bold (I135K change underlined), GHBP (aa 1-238): Uppercase, Linker regions (g4s)4: Uppercase/Bold;FIG. 20A ) nucleotide sequence,FIG. 20B ) protein sequence; -
FIGS. 21A and 21B : PTH-(g4s)4-PTHrExt (I135K)-Hist (Code #14A10), PTH Signal peptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (I135K) (aa 1-159): Lowercase/Bold (I135K change underlined), Linker region (g4s)4: Uppercase/Bold, C-terminal 6× Hist tag: Uppercase/Underlined;FIG. 21A ) nucleotide sequence,FIG. 21B ) protein sequence; -
FIGS. 22A and 22B : PTH-(g4s)4-PTHrExt (I135K)-Hist (Code #14A11-Hist), GH Signal peptide: Lowercase, PTH (aa 1-34): Uppercase/Underlined, PTHrExt (I135K) (aa 1-159): Lowercase/Bold (I135K change underlined), Linker region (g4s)4: Uppercase/Bold, C-terminal 6× Hist tag: Uppercase/Underlined;FIG. 22A ) nucleotide sequence,FIG. 22B ) protein sequence; -
FIG. 23 PTH Sequence (AA 1-84); -
FIG. 24 (SEQ ID NO: 40): PTHrP (1-36); -
FIG. 25 (SEQ ID NO: 41): PTHrP signal sequence; -
FIG. 26 (SEQ ID NO: 4): PTHrP propeptide; -
FIGS. 27A and 27B : Schematic models showing the structure of the PTH fusion molecules.FIG. 27A : PTH (Purple) linked to PTHrExt (Green) which in turn is linked to GHBP (Orange). Linkers shown as grey lines. W104A change shown in blue on GHBP. It is hypothesised that a state of equilibrium exists between PTH bound to PTHrExt (Inactive State: A) and PTH being released and able to bind PTHR1 (Active State, B).FIG. 27B : PTH (Purple) linked to GHBP (Orange). Linker shown as grey line. W104A change shown in blue on GHBP; -
FIGS. 28A, 28B, and 29C : Analysis of purified PTH fusion molecules by 10% SDS-PAGE under non-reducing conditions (Coomassie Stained).FIG. 28A : Lane 1: 5 μg 14A2c Lane 2: 5 μg 14A3b. 14A2c (contains PTH prepropeptide) separates as two diffuse bands from 60-100 kDa. 14A3b (GHss) resolves as a single diffuse band ˜75-100 kDa.FIG. 28B : Lane 3: 6 μg 14A7 Lane 4: 3 μg 14A4. Proteins judged to be >90% pure. Obtained ˜10 mg 14A2c, ˜4 mg 14A3b, 1.42 mg 14A7 and 0.29 mg 14A4 purified protein from a 1 litre roller bottle culture. -
FIG. 28C : Western blot anti PTH 14A2c & 14A3b. Analysis of purified PTH fusion molecules by 10% SDS-PAGE under non-reducing conditions. Samples were transferred to a PVDF membrane and probed with anti-human PTH (1-34) specific antibody. Lanes 1-3: 14A2c at a loading of 125 ng, 250 ng and 500 ng. Lanes 4-6: 14A3b at a loading of 125 ng, 250 ng and 500 ng. 14A2c is more sensitive to detection by anti-PTH antibody. Representative of 3 independent western blot experiments; -
FIG. 29A : In vitro induction of cAMP. UMR-106 cells were challenged with either 500 nM PTH fusion or 100 nM human PTH 1-34 for 15 minutes at 3TC/5% CO2. Cells were lysed and cAMP levels measured using an R & D systems Parameter cAMP Elisa. Data are presented as log pmol cAMP/ml ±SD. An 11-fold increase in cAMP levels was found for 14A2c over 14A3b: mean±SD 264±12 vs 25±0.95 pmol cAMP/ml. Both Fusions showed reduced biological activity when compared to PTH 1-34: mean±SD 2551±186 pmol cAMP/ml. Average of n=1 experiment carried out in duplicate. -
FIG. 29B : Dual Luciferase Reporter Assay for cAMP Activity. UMR-106 cells were transfected with the reporter plasmid pGL4.29/CRE/Luc2/Hygro and transfection control plasmid phRL (Renilla) and challenged with either PTH fusion or human PTH 1-34 for 5 hours at 3TC/5% CO2. Cells were lysed and Luciferase activity measured using the Promega Dual Luciferase Assay kit. Data are presented as fold induction of control ±SD. 14A2c is more bioactive than 14A3b equating to a ˜1.3 to 1.6 fold increase at 100 & 500 nM respectively: mean fold induction±SD, 16.5±1.7, 63±5.9 vs 12.4±1.0, 40.3±3.1. Average of triplicate values. Both Fusions showed reduced biological activity when compared to PTH 1-34 at an equivalent concentration of 100 nM: mean±SD, 67.3±1.6. Representative of 3 separate experiments. -
FIG. 29C : Dual Luciferase Reporter Assay for cAMP Activity Comparison of all 4 PTH fusion molecules. UMR-106 cells were transfected with the reporter plasmid pGL4.29/CRE/Luc2/Hygro and transfection control plasmid phRL (Renilla) and challenged with either PTH fusion or human PTH 1-34 for 5 hours at 37° C./5% CO2. Cells were lysed and Luciferase activity measured using the Promega Dual Luciferase Assay kit. Data are presented as fold induction of control ±SD. Pattern of activity is similar to previous assays for 14A2c & 14A3b vs PTH. Both PTH-GHBP fusion molecules (14A4, 49±4.17 & 14A7, 44±0.42) are more active than the PTH-PTHrExt-GHBP fusion molecules (14A2c, 15±0.09 & 14A3b, 7.7±3.13) at 100 nM. At 100 nM both 14A4 and 14A7 have comparable activity to PTH (54±2.7). -
FIG. 29D : Determination of EC50 values for PTH & PTH fusions using the Dual Luciferase Reporter Assay. PTH has an EC50 of 32±10.67 nM (n=4 experiments) and is ˜18-fold more potent than 14A2c (EC50=579±138 nM, n=3 experiments), 28-fold more potent than 14A3b (EC50=896 nM, n=1), and 4.7-fold more potent than 14A7 (EC50=153 nM, n=1 experiment). - The Sequence Listing is submitted as an ASCII text file in the form of the file name “Sequence.txt,” 163,840 bytes, created on Mar. 18, 2022, which is incorporated by reference herein.
-
TABLE 1 Code (SEQ ID) Molecule Description 14A1 (12) PTHss-PTH-(g4s)4-PTHrExt-(g4s)4-GHBP 14A2 (13) PTHss-pp-PTH-(g4s)4-PTHrExt-(g4s)4-GHBP 14A3 (14) GHss-PTH-(g4s)4-PTHrExt-(g4s)4-GHBP 14A4 (15) GHss-PTH-(g4s)4-GHBP 14A5 (16) GHss-PTH-(g4s)4-PTHrExt 14A5_Hist (17) GHss-PTH-(g4s)4-PTHrExt-Hist 14A6_Hist (18) PTHss-pp-PTH-(g4s)4-PTHrExt-Hist 14A6 (19) PTHss-pp-PTH-(g4s)4-PTHrExt 14A7 (20) PTHss-pp-PTH-(g4s)4-GHBP 14A8 (21) PTHss-pp-PTH-(g4s)4-PTHrExt (I135K)-(g4s)4- GHBP 14A9 (22) GHss-PTH-(g4s)4-PTHrExt (I135K)-(g4s)4-GHBP 14A10_Hist (23) PTHss-pp-PTH-(g4s)4-PTHrExt (I135K)- Hist 14A11_Hist (24) GHss-pp-PTH-(g4s)4-PTHrExt (I135K)-Hist 14A12 (25) PTHss-pp-LA:PTH-(g4s)4-PTHrExt-(g4s)4-GHBP 14A13 (26) GHss-LA:PTH-(g4s)4-PTHrExt-(g4s)4-GHBP 14A15 (27) PTHss-pp-LA:PTH-(g4s)4-GHBP 14A16 (28) GHss-LA:PTH-(g4s)4-GHBP 14A17 (29) PTHss-pp-LA:PTH-(g4s)4-PTHrExt-Hist 14A18 (30) GHss-LA:PTH-(g4s)4-PTHrExt-Hist 14A19 (31) PTHss-pp-PTH (1-84)-(g4s)4-PTHrExt-(g4s)4- GHBP 14A20 (32) GHss-PTH (1-84)-(g4s)4-PTHrExt-(g4s)4-GHBP 14A21 (33) PTHss-pp-PTH (1-84)-(g4s)4-GHBP 14A22 (34) GHss-PTH (1-84)-(g4s)4-GHBP 14A23 (35) PTHss-pp-PTH (1-84)-(g4s)4-PTHrExt-Hist 14A24 (36) GHss-PTH (1-84)-(g4s)4-PTHrExt-Hist PTHss = Parathyroid Hormone secretion signal; pp = proppeptide; GHss = Growth hormone secretion signal; PTH = (aa 1-34 or 1-84 as stated or fragments thereof); PTHrExt = PTH receptor extracellular domain; GHBP = Growth hormone binding protein (aa 1-238); (g4s)4 = 4 repeats of amino acids GGGGS (residues 66-85 of SEQ ID NO: 20); Hist tagged = HHHHHH (residues 242-247 of SEQ ID NO: 17); I135K = mutation of Isoleucine-135 to lysine in PTHrExt:LA:PTH = long acting PTH [fusion of PTH 1-14 with PTHrP as described in text]. - Linker regions in the above fusions are composed of multiples of GGGGS. In the examples given in Table 1 the linker regions are composed of 4×GGGGS (residues 66-85 of SEQ ID NO: 20), but variable multiples can be used.
- The I135K change present in PTHrExt in selected constructs has been shown to reduce the binding of PTH for the receptor. Other amino acid changes can also be used in combination or as single point mutations such as D137A, P132L & L187A. (SEQ ID NO: 56).
- The numbering for the PTHrExt in the sequences below refer to the mature protein processed at Alanine 28 and therefore D29-I187 is thus referred to as amino acids 1-159 (SEQ ID NO: 3) in the following sequences.
- All of above PTH sequences can be replaced with PTH 1-84 if desired and variables thereof.
-
TABLE 2 List of all Proposed PTHrP Fusion Constructs (SEQ ID 42-53) Molecule Description 14A25 (42) PTHrPss-pp-PTHrP-(g4s)4-PTHrExt-(g4s)4-GHBP 14A26 (43) GHss-PTHrP-(g4s)4-PTHrExt-(g4s)4-GHBP 14A27 (44) GHss-PTHrP-(g45)4-GHBP 14A28 (45) GHss-PTHrP-(g45)4-PTHrExt 14A29_Hist (46) GHss-PTHrP-(g4s)4-PTHrExt-Hist 14A30_Hist (47) PTHrPss-pp-PTHrP-(g4s)4-PTHrExt-Hist 14A31 (48) PTHrPss-pp-PTHrP-(g4s)4-PTHrExt 14A32 (49) PTHrPss-pp-PTHrP-(g4s)4-GHBP 14A33 (50) PTHrPss-pp-PTHrP-(g4s)4-PTHrExt (I135K)-(g4s)4- GHBP 14A34 (51) GHss-PTHrP-(g45)4-PTHrExt (I135K)-(g4s)4-GHBP 14A35_Hist (52) PTHrPss-pp-PTHrP-(g4s)4-PTHrExt (I135K)-Hist 14A36_Hist (53) GHss-pp-PTHrP-(g4s)4-PTHrExt (I135K)-Hist - PTHrPss=Parathyroid Hormone related protein secretion signal; pp=proppeptide; GHss=Growth hormone secretion signal; PTHrP=(aa 1-36 or fragments thereof); PTHrExt=PTH receptor extracellular domain; GHBP=Growth hormone binding protein (aa 1-238); (g4s)4=4 repeats of amino acids GGGGS (residues 66-85 of SEQ ID NO: 20); Hist tagged=HHHHHH (residues 242-247 of SEQ ID NO: 17); I135K=mutation of Isoleucine-135 to lysine in PTHrExt
-
TABLE 3 SEQ ID NUMBER SUMMARY SEQ ID NO Name 1 PTH Signal Peptide: MIPAKDMAKVMIVMLAICFLTKSDG 2 GH Secretion signal: MATGSRTSLLLAFGLLCLPWLQEGSA 3 PTH receptor ECD (1-159): DDVMTKEEQIFLLHRAQAQCEKRLKEVLQRPASIMESDKGWTSASTSGKPRK DKASGKLYPESEEDKEAPTGSRYRGRPCLPEWDHILCWPLGAPGEVVAVPCP DYIYDFNHKGHAYRRCDRNGSWELVPGHNRTWANYSECVKFLTNETREREV FDRL 4 PTHrP propeptide: rsveglsrrl 5 GH receptor ECD (1-238): FSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPERETFSCHWTD EVHHGTKNLGPIQLFYTRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTSIW IPYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEA PRNADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVR VRSKQRNSGNYGEFSEVLYVTLPQMSQ 7 GH ECD substitution: w104a substitution FSGSEATAAILSRAPWSLQSVNPGLKTNSSKEPKFTKCRSPERETFSCHWTD EVHHGTKNLGPIQLFYIRRNTQEWTQEWKECPDYVSAGENSCYFNSSFTSIAI PYCIKLTSNGGTVDEKCFSVDEIVQPDPPIALNWTLLNVSLTGIHADIQVRWEA PRNADIQKGWMVLEYELQYKEVNETKWKMMDPILTTSVPVYSLKVDKEYEVR VRSKQRNSGNYGEFSEVLYVTLPQMSQ 8 PTH formula (I): general AA formula (1-36) 9 PTH 1-84: SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFVALGAPLAPRDAGSQRPR KKEDNVLVESHEKSLGEADKADVNVLTKAKSQ 10 PTH defined formula (I): Ala-Val-Ala-Glu-Ile-Gln-Leu-Met-His-Gln-Arg-Ala-Lys- Trp-Ile-Gln-Asp-Ala-Arg-Arg-Arg-Ala-Phe-Leu-His-Lys-Leu-Ile-Ala-Glu-Ile-His- Thr-Ala-Glu-Ile, or a fragment thereof including amino acids 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35 of said sequence. (1-36) 11 PTH Propeptide: ksvkkr 12-36 Constructs of table 1 37 PTH short (LA PTH): LA-PTH ([Ala1,3,12,Gln10,Arg11,Trp14]PTH(1- 14)/[Ala18,22,Lys26]PTHrP(15-36)COOH) 40 PTHrP (1-36): AVSEHQLLHDKGKSIQDLRRRFFLHHLIAEIHTAEI 41 PTHrP signal sequence: MQRRLVQQWSVAVFLLSYAVPSCG 42-53 Constructs of table 2 54 PTH 1-34: SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF 55 PTH ECD Signal peptide: MGTARIAPGLALLLCCPVLSSAYALVDA 56 PTH receptor full length: MGTARIAPGLALLLCCPVLSSAYALVDADDVMTKEEQIFLLHRAQAQCEKRLKE VLQRPASIMESDKGWTSASTSGKPRKDKASGKLYPESEEDKEAPTGSRYRGR PCLPEWDHILCWPLGAPGEVVAVPCPDYIYDFNHKGHAYRRCDRNGSWELV PGHNRTWANYSECVKFLTNETREREVFDRLGMIYTVGYSVSLASLTVAVLILAY FRRLHCTRNYIHMHLFLSFMLRAVSIFVKDAVLYSGATLDEAERLTEEELRAIAQ APPPPATAAAGYAGCRVAVTFFLYFLATNYYWILVEGLYLHSLIFMAFFSEKKY LWGFTVFGWGLPAVFVAVWVSVRATLANTGCWDLSSGNKKWIIQVPILASIVL NFILFINIVRVLATKLRETNAGRCDTRQQYRKLLKSTLVLMPLFGVHYIVFMATP YTEVSGTLWQVQMHYEMLFNSFQGFFVAIIYCFCNGEVQAEIKKSWSRWTLA LDFKRKARSGSSSYSYGPMVSHTSVTNVGPRVGLGLPLSPRLLPTATTNGHP QLPGHAKPGTPALETLETTPPAMAAPKDDGFLNGSCSGLDEEASGPERPPAL LQEEWETVM 57 Fusion of SEQ ID NO: 1, 11 and 9 58 DNA sequence encoding SEQ ID NO: 57 59 DNA sequence encoding SEQ ID NO: 59 60 Fusion of SEQ ID NO: 1 and 11 61 DNA sequence encoding SEQ ID NO: 60 62 DNA sequence encoding SEQ ID NO: 56 63 DNA sequence encoding SEQ ID NO: 3 64 DNA sequence encoding SEQ ID NO: 7 65 DNA sequence encoding SEQ ID NO: 2 66 DNA sequence encoding SEQ ID NO: 12 67 DNA sequence encoding SEQ ID NO: 13 68 DNA sequence encoding SEQ ID NO: 14 69 DNA sequence encoding SEQ ID NO: 15 70 DNA sequence encoding SEQ ID NO: 17 71 DNA sequence encoding SEQ ID NO: 16 72 DNA sequence encoding SEQ ID NO: 18 73 DNA sequence encoding SEQ ID NO: 19 74 DNA sequence encoding SEQ ID NO: 20 75 DNA sequence encoding SEQ ID NO: 21 39 DNA sequence encoding SEQ ID NO: 22 38 DNA sequence encoding SEQ ID NO: 23 6 DNA sequence encoding SEQ ID NO: 24 - Construction of PTH fusions: Molecules were constructed by a combination of gene synthesis (Eurofin MWG) and standard DNA manipulation techniques. Recombinant genes encoding full length PTH fusions were cloned into a modified mammalian expression plasmid, pSecTag/FRT/V5/Hist-TOPO (Invitrogen). Stable cell lines were produced in the CHO Flp-In cell line (Invitrogen) according to manufacturer's instructions and adapted to serum free media in Hyclone SFM4CHO Utility (Thermo Scientific). PTH fusions were under the secreted expression of either the PTH or GH signal peptides.
- Expression and Purification: Cells were maintained in roller bottle cultures in Hyclone SFM4CHO Utility medium with passaging every 2-3 days, keeping cell densities between 0.25×106 viable cells/ml (VCPM) and 1.5×106 VCPM. For expression studies, roller bottles were seeded at 0.5×106 VCPM and grown at 37° C., 5% CO2 and allowed to reach 1×106 VPCM. Valproic acid was added to a final concentration of 2 mM and the temperature reduced to 31° C. Cells were grown for up to 8-10 days with viability still at ˜70% when harvest was clarified by centrifugation at 22,000×g using a Beckman JLA 16-25 rotor for 20 minutes at 4° C. EDTA and Benzamidine-HCl were added to final concentrations of 5 and 10 mM respectively and the medium concentrated using a
Vivaflow 200 tangential flow concentrator and stored frozen at −20° C. Target protein was purified from this concentrate by anion exchange (Q-Sepharose FF, GE Healthcare) and affinity chromatography (anti GHBP antibody column). Protein concentrations were measured by Bradford protein assay and samples analysed by SDS-PAGE under non-reducing conditions and either stained with coomassie blue or western blotted using a commercial anti-PTH 1-34 antibody (Abcam 14493) or an in house developed anti GHBP antibody. Purified samples were aliquoted and stored at −80° C. - In Vitro Bioactivity: Purified proteins were tested for their ability to stimulate cAMP production from the PTH responsive cell line, UMR-106 (rat osteoblastic like cell line). Cells were stimulated for 15 minutes in the presence of test molecules and cAMP levels measured from cell lysates using a cAMP specific Elisa (R&D systems).
- Animal Model for Hypoparathyroidism Shimizu et al have used an animal model for hypoparathyroidism in their studies on LA-PT. In this model rats were thyroparathyroidectomized (TPTX) prior to treatment. Briefly: Surgical TPTX was performed on 6-week-old rats obtained from Charles River Laboratories Japan, Inc. After surgery, pellet food (CE-2; CLEA Japan, Inc., Tokyo, Japan) containing 1.10% calcium and 1.09% phosphate moisturized with tap water was supplied inside each cage for easy access and digestion in sham-operated and TPTX rats. Postsurgical rats exhibiting sCa levels less than 8.0 mg/dL at 5 days after TPTX surgery were selected for subsequent peptide injection studies from the next day.
- From the crystal structure analysis of PTH with the N-domain PTH receptor [1], the PTH is shown to sit in a groove formed by the N-terminal receptor portion. It is this mode of interaction that is hypothesised to protect PTH from degradation and to create an “inactive pool” of PTH, thus prolonging its biological activity to create a long acting PTH. It is proposed that the new molecules (See
FIG. 1 ) will be fusions between PTH (residues 1-34), the N-terminal PTH receptor domain (PTHrExt, most commonly residues D29-L187 but not restricted to other combinations) and the growth hormone binding protein (GHBP, residues 1-238). GHBP is an inert moiety designed to increase Mw & therefore delay clearance. It will contain a W104A mutation to prevent interaction with GH in the circulation. - Initial expression studies showed that we are able to express and purify a PTH fusion molecule from a CHO cell line at sufficient levels (˜10 mg/L) to justify further progress. All molecules appear to be intact and >95% pure as judged by SDS-PAGE.
- Both PTH fusion molecules so far tested are biologically activity and produce a dose response in an in vitro cAMP assay.
- PTH1-34 has been fused to growth hormone binding protein (GHbp) with or without the extracellular domain of the PTH receptor (PTHextR). Molecules have then been expressed with either the GH (GHss) or PTH (PTHss) signal sequence and propeptide (pp). Thus, the following 4 molecules have been generated:
-
- 14A2c=PTHss-pp-PTH (1-34)-(g4s)4-PTHrExt-(g4s)4-GHbp (SEQ ID NO: 13)
- 14A3b=GHss-PTH (1-34)-(g4s)4-PTHrExt-(g4s)4-GHbp (SEQ ID NO: 14)
- 14A4=GHss-PTH (1-34)-(g4s)4-GHbp (SEQ ID NO: 15)
- 14A7=PTHss-pp-PTH(1-34)-(g4s)4-GHbp (SEQ ID NO: 20)
- Stable clones for all 4 molecules have been generated, all stable clones expressed protein and all 4 proteins have been purified on an affinity column for GHbp. Those using the GHss are expressed at a lower level and SDS-PAGE analysis and bioassays suggest that there may be incomplete processing of the translated product with additional aa at the N-terminus and possibly differential glycosylation of those with the GHss compared to those with the PTHss. (
FIG. 28 ) This would fit with PTH requiring its own signal sequence for complete processing of the preproPTH sequence, which is in the design of the molecules with the PTHss. All molecules show bioactivity in the two bioassays used and evidence suggests that the molecule that includes the PTHextR is less bioactive (FIGS. 29 and 30 ). - PTH Fusion Molecules: Design & Hypothesis
- Parathyroid hormone (PTH) is an 84-aa peptide with biological activity residing in residues 1-34. PTH is produced by the parathyroid glands in response to low serum calcium levels. PTH acts on the parathyroid receptor (PTHR1) on bone and kidney promoting the release of calcium from bone, slowing excretion of calcium from kidneys, increasing absorption from intestines and promoting renal excretion of phosphate. In Hypoparathyroidism (HypoPT) the parathyroid glands are either absent or damaged and therefore cannot produce any or sufficient amounts of parathyroid hormone. Initial treatment is with oral calcium and active VD3 supplements. Recently, replacement of PTH in HypoPT with Natpara (PTH 1-84) has been licensed but requires daily sc injections and is complicated by fluctuating calcium levels. Continuous pump therapy is effective but impractical for most patients. There is therefore an unmet need for a long acting PTH molecule that provides constant physiological levels of PTH activity. Previously we have shown that the fusion of growth hormone to its binding protein (GHBP) can generate a long-acting growth hormone (1). Using this technology we have generated a number of PTH fusion molecules (See
FIGS. 1A & B). The PTH fusions are predicted to have a prolonged circulating half-life through increased protein size, whilst retaining biological activity. As a further modification of the PTH fusion shown inFIG. 1A , it is hypothesised that PTH will form intramolecular interactions with PTHrExt, be protected from degradation, and provide an intravascular pool of active PTH. To prevent GH binding, a single amino acid change of tryptophan-104 to alanine in the GHBP moiety (W104A) will be introduced in to all PTH fusion molecules. All PTH fusion will be expressed using either the naturally occurring PTH prepropeptide sequence or the GH secretion signal. -
- Shimizu, M., et al., Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys. J Bone Miner Res, 2016. 31(7): p. 1405-12
Claims (24)
1. A fusion polypeptide comprising
a polypeptide comprising an amino acid sequence of a parathyroid hormone or biologically active fragment or analogue thereof,
a polypeptide comprising an amino acid sequence of a growth hormone binding domain of growth hormone receptor or fragment or analogue thereof, wherein said parathyroid hormone or biologically active fragment or analogue thereof is linked either directly or indirectly as a translational fusion to said growth hormone binding domain of growth hormone receptor.
2. The fusion polypeptide according to claim 1 , wherein said fusion polypeptide comprises a parathyroid hormone comprising or consisting of:
the amino acid sequence set forth in SEQ ID NO: 10 or SEQ ID NO: 9; or
a fragment of SEQ ID NO: 10 including amino acids 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35 of SEQ ID NO: 10, or a fragment of SEQ ID NO: 9 including amino acids 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35 of SEQ ID NO: 9.
3. The fusion polypeptide according to claim 2 wherein said fusion polypeptide comprises a parathyroid hormone comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 54.
4. The fusion polypeptide according to claim 1 wherein said fusion polypeptide comprises a parathyroid hormone analogue comprising or consisting of the amino acid sequence of formula (I):
(I) where Xaa01 is Ser or Ala; Xaa03 is Ser or Ala; Xaa08 is Met or Leu; Xaa10 is Asn, Ala, Val, Asp, Glu, or Gln; Xaa11 is Leu, Ala, Val, Met, Lys, Arg, or Trp; Xaa12 is Gly, Ala, His, or Arg; Xaa13 is Lys, Ala, Leu, Gln, Arg, His, or Trp; Xaa14 is His, Leu, Arg, Phe, Trp, or Ser; Xaa16 is Gln or Asn; Xaa17 is Asp or Ser; Xaa18 is Ala, Leu, Met, Glu, Ser, or Phe; Xaa22 is Ala, Phe, Glu, Ser, Leu, Asn, Trp, or Lys; Xaa25 is His, Arg, Leu, Trp, or Lys; and Xaa26 is Lys, His, Ala, Ser, Asn, or Arg or a fragment thereof including amino acids 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35 of formula (I), with the proviso that at least one of Xaa18 is not Leu or Met, Xaa22 is not Phe, and Xaa26 is not His.
5. The fusion polypeptide according to claim 1 wherein said fusion polypeptide comprises:
a parathyroid hormone and a parathyroid hormone analogue amino acid sequence comprising or consisting of the amino acid sequence set forth in SEQ ID NO: 37; or
a parathyroid hormone related protein or biologically active fragment or analogue thereof, comprising the amino acid sequence set forth in SEQ ID NO: 40.
6. The fusion polypeptide according to claim 1 wherein said fusion polypeptide comprises:
the extracellular growth hormone binding domain polypeptide of human growth hormone receptor; or
an extracellular growth hormone binding domain polypeptide comprising of the amino acid sequence set forth in SEQ ID NO: 5.
7. The fusion polypeptide according to claim 6 wherein said fusion polypeptide comprises:
a modified extracellular growth hormone binding domain polypeptide wherein said modification is by addition, deletion or substitution of at least one amino acid residue wherein said modified polypeptide substantially lacks growth hormone binding activity or has reduced growth hormone binding activity;
a modification of one or more of the amino acid residues selected from the group consisting of: W169, R43, E44, I103, W104, I105, P106, I164 and D165 as set forth in SEQ ID NO: 5;
a deletion or substitution of amino acid residue tryptophan 104 of the amino acid sequence set forth in SEQ ID NO: 5; or
a substitution of tryptophan 104 for alanine as set forth in SEQ ID NO: 5.
8. The fusion polypeptide according to claim 1 wherein said fusion polypeptide comprises or consists of a parathyroid hormone fragment comprising or consisting of the amino acid residues 1-28, 1-29, 1-30, 1-31, 1-32, 1-33, 1-34, or 1-35 of SEQ ID NO: 8.
9. The fusion polypeptide according to claim 8 wherein said fusion polypeptide comprises or consists of the amino acid sequence set forth in SEQ ID NO: 54 wherein said parathyroid hormone amino acid sequence is modified by addition, deletion or substitution of at least one amino acid residue and wherein said modified fusion polypeptide retains parathyroid hormone activity.
10. The fusion polypeptide according to claim 1 wherein said fusion polypeptide comprises a growth hormone binding domain polypeptide wherein said growth hormone binding domain polypeptide is located at the carboxyl terminal end or amino terminal end of said fusion polypeptide.
11. The fusion polypeptide according to claim 1 wherein said fusion polypeptide comprises a pro-peptide and/or a peptide secretion signal.
12. The fusion polypeptide according to claim 1 wherein said fusion polypeptide comprises a parathyroid hormone, fragment or analogue thereof and is linked directly or indirectly to said growth hormone binding domain polypeptide of growth hormone receptor by a peptide linker and/or is directly linked to said receptor polypeptide as an in-frame translational fusion.
13. A nucleic acid molecule that encodes a fusion polypeptide according to claim 1 .
14. A vector comprising a nucleic acid molecule according to claim 13 .
15. An isolated cell transfected or transformed with a nucleic acid molecule according to claim 13 or a vector comprising the nucleic acid molecule.
16. A method for the production of a fusion polypeptide comprising the steps consisting of:
i) providing a cell transfected or transformed with a nucleic acid molecule encoding the fusion polypeptide of claim 1 or a vector comprising the nucleic acid molecule and cell culture medium;
ii) culturing said cell; and
iii) isolating the fusion polypeptide from said cell or medium.
17. A pharmaceutical composition comprising a fusion polypeptide according to claim 1 including an excipient or carrier.
18. A method of treating hypoparathyroidism in a subject comprising administering the fusion polypeptide according to claim 1 to the subject.
19. A method of treating osteoporosis in a human subject comprising administering the fusion polypeptide according to claim 1 to the human subject.
20. The method of claim 19 wherein said fusion polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 40.
21. The method of claim 19 wherein said fusion polypeptide is administered to the subject in combination with calcium carbonate and/or vitamin D supplements such as calcitrol or alfacalcitrol.
22. The fusion polypeptide according to claim 1 , wherein said fusion polypeptide comprises or consists of an amino acid sequence set forth in SEQ ID NO: 20, 27, 28, 33 or 34.
23. The fusion polypeptide according to claim 1 , wherein said fusion polypeptide comprises or consists of an amino acid sequence set forth in SEQ ID NO: 20.
24. The fusion polypeptide according to claim 1 , wherein said fusion polypeptide comprises or consists of an amino acid sequence set forth in SEQ ID NO: 27.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/708,394 US20220218790A1 (en) | 2017-04-28 | 2022-03-30 | Parathyroid hormone fusion polypeptide |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1706781.0A GB201706781D0 (en) | 2017-04-28 | 2017-04-28 | Parathyroid hormone fusion polypeptide |
GB1706781.0 | 2017-04-28 | ||
PCT/GB2018/051120 WO2018197895A2 (en) | 2017-04-28 | 2018-04-27 | Parathyroid hormone fusion polypeptide |
US201916608611A | 2019-10-25 | 2019-10-25 | |
US17/708,394 US20220218790A1 (en) | 2017-04-28 | 2022-03-30 | Parathyroid hormone fusion polypeptide |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2018/051120 Continuation WO2018197895A2 (en) | 2017-04-28 | 2018-04-27 | Parathyroid hormone fusion polypeptide |
US16/608,611 Continuation US11344606B2 (en) | 2017-04-28 | 2018-04-27 | Parathyroid hormone fusion polypeptide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220218790A1 true US20220218790A1 (en) | 2022-07-14 |
Family
ID=59011076
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/608,611 Active 2038-10-06 US11344606B2 (en) | 2017-04-28 | 2018-04-27 | Parathyroid hormone fusion polypeptide |
US17/708,394 Pending US20220218790A1 (en) | 2017-04-28 | 2022-03-30 | Parathyroid hormone fusion polypeptide |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/608,611 Active 2038-10-06 US11344606B2 (en) | 2017-04-28 | 2018-04-27 | Parathyroid hormone fusion polypeptide |
Country Status (7)
Country | Link |
---|---|
US (2) | US11344606B2 (en) |
EP (1) | EP3609913A2 (en) |
JP (2) | JP2020519250A (en) |
CN (1) | CN110546159B (en) |
CA (1) | CA3061088A1 (en) |
GB (1) | GB201706781D0 (en) |
WO (1) | WO2018197895A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201706781D0 (en) * | 2017-04-28 | 2017-06-14 | Univ Sheffield | Parathyroid hormone fusion polypeptide |
IL284533B2 (en) | 2019-01-11 | 2024-02-01 | Radius Health Inc | Methods for detecting neutralizing antibodies to parathyroid hormone (pth) and parathyroid hormone-related peptide (pthrp) analog |
CN111876388A (en) * | 2020-07-24 | 2020-11-03 | 赛瑞诚(苏州)生物科技有限公司 | Bone and bone tissue targeted exosome and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011143406A2 (en) * | 2010-05-13 | 2011-11-17 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
WO2012123734A1 (en) * | 2011-03-15 | 2012-09-20 | Asterion Limited | Modified receptor fusion proteins |
US11344606B2 (en) * | 2017-04-28 | 2022-05-31 | University Of Sheffield | Parathyroid hormone fusion polypeptide |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6770623B1 (en) | 1997-12-09 | 2004-08-03 | Eli Lilly And Company | Stabilized teriparatide solutions |
JPH11285388A (en) | 1998-04-03 | 1999-10-19 | Jcr Pharmaceuticals Co Ltd | Chimera receptor expression cell and use thereof |
JP5356636B2 (en) | 2000-04-21 | 2013-12-04 | タフツ メディカル センター インコーポレイテッド | Agonists and antagonists of G protein-coupled receptors (GPCRs) and methods for using them to activate and inhibit GPCRs |
AU2005266184A1 (en) | 2004-07-26 | 2006-02-02 | Asterion Limited | Linkers |
KR100700869B1 (en) | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | The stabilized parathyroid hormone composition comprising parathyroid hormone buffer and stabilizing agent |
CA2930681C (en) | 2007-04-09 | 2019-10-15 | The Board Of Trustees Of The University Of Arkansas | Fusion protein of collagen-binding domain and parathyroid hormone |
GB0717985D0 (en) | 2007-07-20 | 2007-10-24 | Asterion Ltd | Growth hormone fusion proteins |
WO2010111617A2 (en) | 2009-03-27 | 2010-09-30 | Van Andel Research Institute | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use |
EP2536754A1 (en) | 2010-02-16 | 2012-12-26 | Novo Nordisk A/S | Factor viii fusion protein |
WO2013120060A1 (en) | 2012-02-09 | 2013-08-15 | The Board Of Trustees Of The University Of Arkansas | Delivery of therapeutic agents by a collagen binding protein |
CA2859412C (en) | 2011-12-14 | 2021-05-25 | The Board Of Trustees Of The University Of Arkansas | Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments |
RU2014133818A (en) | 2012-01-20 | 2016-03-20 | Люпин Лимитед | STABILIZED PTH COMPOSITION |
CA2919477A1 (en) * | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
JP6805174B2 (en) | 2015-05-12 | 2020-12-23 | アメリカ合衆国 | AAV isolates and fusion proteins containing nerve growth factor signal peptides and parathyroid hormone |
-
2017
- 2017-04-28 GB GBGB1706781.0A patent/GB201706781D0/en not_active Ceased
-
2018
- 2018-04-27 CA CA3061088A patent/CA3061088A1/en active Pending
- 2018-04-27 JP JP2019558571A patent/JP2020519250A/en active Pending
- 2018-04-27 EP EP18782783.7A patent/EP3609913A2/en active Pending
- 2018-04-27 US US16/608,611 patent/US11344606B2/en active Active
- 2018-04-27 CN CN201880027437.0A patent/CN110546159B/en active Active
- 2018-04-27 WO PCT/GB2018/051120 patent/WO2018197895A2/en unknown
-
2022
- 2022-03-30 US US17/708,394 patent/US20220218790A1/en active Pending
- 2022-12-19 JP JP2022202078A patent/JP2023027315A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011143406A2 (en) * | 2010-05-13 | 2011-11-17 | The General Hospital Corporation | Parathyroid hormone analogs and uses thereof |
WO2012123734A1 (en) * | 2011-03-15 | 2012-09-20 | Asterion Limited | Modified receptor fusion proteins |
US11344606B2 (en) * | 2017-04-28 | 2022-05-31 | University Of Sheffield | Parathyroid hormone fusion polypeptide |
Also Published As
Publication number | Publication date |
---|---|
EP3609913A2 (en) | 2020-02-19 |
WO2018197895A3 (en) | 2019-01-17 |
JP2023027315A (en) | 2023-03-01 |
US11344606B2 (en) | 2022-05-31 |
CN110546159B (en) | 2023-08-22 |
JP2020519250A (en) | 2020-07-02 |
CN110546159A (en) | 2019-12-06 |
CA3061088A1 (en) | 2018-11-01 |
US20200164033A1 (en) | 2020-05-28 |
WO2018197895A2 (en) | 2018-11-01 |
GB201706781D0 (en) | 2017-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220218790A1 (en) | Parathyroid hormone fusion polypeptide | |
AU2002213843B2 (en) | Apolipoprotein analogues | |
EP2581389A1 (en) | Fusion protein of exendin-4 and its analog, preparation method and use thereof | |
US7223726B2 (en) | Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same | |
AU2211195A (en) | Human bone stimulating factor | |
US20200140516A1 (en) | Insulin analogues with enhanced stability and reduced mitogenicity | |
US20180333464A1 (en) | Methods of using interleukin-10 for treating diseases and disorders | |
EP0748817A2 (en) | Parathyroid hormone derivatives and their use | |
US20150344540A1 (en) | Novel glp-1 receptor agonists with cholesterol efflux activity | |
JP2018505874A (en) | Insulin analogues with selective signaling properties and lower mitogenicity | |
CN113105561B (en) | Preparation method and application of double-target fusion protein | |
US20220135640A1 (en) | Cortistatin or an analogue thereof as a pharmaceutically active agent in latent form | |
EP0586667A1 (en) | Refolding and purification of insulin-like growth factor i | |
WO1996040909A1 (en) | Bone stimulating factor | |
IE914484A1 (en) | Oxidation resistant variants of parathyroid hormone | |
WO2015193378A1 (en) | Novel glp-1 receptor agonists with cholesterol efflux activity | |
Rand-Weaver et al. | A rapid procedure for the isolation of bioactive growth hormone | |
KR20180132833A (en) | Methylmalonyl coenzyme A mutase (MCM) fusion constructs for the treatment of disorders associated with MCM deficiency | |
EP2864353B1 (en) | Selective cartilage therapy | |
RU2792236C9 (en) | Polypeptide derivative and method for its production | |
RU2792236C1 (en) | Polypeptide derivative and method for its production | |
AU2008201887A1 (en) | Apolipoprotein analogues | |
US20130160166A1 (en) | Oral insulin therapy | |
RU2119800C1 (en) | Growth hormone factor peptide analog and method and composition for stimulating growth hormone secretion | |
US20030027753A1 (en) | Bone stimulating factor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF SHEFFIELD, GREAT BRITAIN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WILKINSON, IAN;ROSS, RICHARD;REEL/FRAME:059469/0413 Effective date: 20191016 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |